STOCK TITAN

Radnostix Q3 loss widens to $842K as sales fall 22%

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

RADNOSTIX INC. (INIS) reported third-quarter product sales of $2,571,035, down 22% from $3,277,816, and a net loss of $842,242 versus $203,601. For the nine months, sales fell 25% to $7,621,744 and net loss widened to $3,072,325 from $477,080. Operating cash flow was negative $1,132,543, compared with positive $210,043 in the prior-year period; cash and equivalents were $711,288 at September 30, 2026.

Sales declines reflected early-2026 voluntary product recalls, delayed cobalt contracts and cobalt-57 and gadolinium-153 supply interruptions. Sodium iodide I-131 sales volumes were fully restored starting July 2026; both recalls were fully executed, with formal FDA closeout pending. Health Canada approved registration of line geometry sources in November 2026, and Radnostix shipped commercial Gd-153 batches that month.

Radnostix agreed with Nano Nuclear Energy Inc. and its wholly owned subsidiary HALEU Energy Fuel Inc. to sell its Fluorine Products and planned uranium de-conversion facility assets for $13.5 million. The company received $0.5 million in escrowed funds in October 2026; at closing, it is to receive $9 million cash and $4 million in restricted NNE shares, subject to customary and other conditions.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 3 points

How the balance works

Positive

  • None.

Negative

  • Moderate pointSales fell 22% in Q3 and 25% over nine months.
  • Moderate pointNet loss reached $842,242 in Q3 and $3,072,325 for nine months.
  • Moderate pointNine-month operating cash flow shifted from $210,043 provided to $1,132,543 used.
Third-quarter product sales $2,571,035 Three months ended September 30, 2026; down 22% from $3,277,816 in 2025.
Nine-month product sales $7,621,744 Nine months ended September 30, 2026; down 25% from $10,172,036 in 2025.
Third-quarter net loss ($842,242) Three months ended September 30, 2026, compared with ($203,601) in 2025.
Nine-month net loss ($3,072,325) Nine months ended September 30, 2026, compared with ($477,080) in 2025.
Operating cash flow ($1,132,543) Cash used in operating activities for the nine months ended September 30, 2026; $210,043 was provided in 2025.
Cash and cash equivalents $711,288 At September 30, 2026.
DUF6 sale consideration $13.5 million Aggregate consideration under the asset purchase agreement, subject to closing conditions.
Revolving line of credit $1.0 million 12-month facility entered into with Bank of Commerce in October 2026.
Type II Drug Master File regulatory
"submitted a Type II Drug Master File to the FDA"
A Type II Drug Master File is a confidential regulatory submission that contains detailed information about a drug’s active substance (the active pharmaceutical ingredient), its intermediates, and the manufacturing processes and controls used to make them. Think of it as a secure technical dossier manufacturers share with regulators and with companies that reference the file when seeking marketing approval, so investors can track whether a supplier’s manufacturing and quality documentation are in place for a product’s regulatory review.
Class II recall medical
"a voluntary Class II recall of our Generic Sodium Iodide I-131"
Class III recall medical
"initiated a voluntary Class III recall of specific lots"
New Drug Application regulatory
"approval of their own New Drug Application"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.
volume-weighted average price financial
"determined based on the volume-weighted average price"
Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.
anti-dilutive financial
"not included in the computation because they would be anti-dilutive"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What conditions must be met for INIS's $13.5 million asset sale to close?

Closing is subject to customary and other conditions, including NRC approval of the transfer and Nano Nuclear Energy Inc. acquiring fee simple title or a valid leasehold interest in the Lea County, New Mexico project site.

What are the terms of INIS's October 2026 revolving credit line?

Radnostix entered a $1.0 million revolving line of credit with Bank of Commerce for a 12-month term at the prime rate. Borrowing limits depend on eligible accounts receivable and inventory, and the facility is secured by accounts receivable, inventory and equipment.

What is the status of INIS's FDA recall closeout?

Both recalls were fully executed, and Radnostix submitted the required documentation to the FDA in June 2026. The FDA acknowledged the recall termination request and advised the company of a recall termination backlog; formal closeout remained pending.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001038277 RADNOSTIX INC false --12-31 Q3 2026 0.01 0.01 750,000,000 750,000,000 542,145,510 542,145,510 528,209,538 528,209,538 5 http://www.intisoid.com/20260930#DUF6Member 24,912,500 40,500,000 4,063 26,637,500 3,000,000 4,063 0 0.10 0.15 0.20 0.25 http://www.intisoid.com/20260930#OutOfPeriodAdjustmentMember 243,780 243,780 3 3 1 1 10 5 5 5 false 00010382772026-01-012026-09-30 xbrli:shares 00010382772026-11-16 iso4217:USD 00010382772026-09-30 00010382772025-12-31 0001038277us-gaap:NonrelatedPartyMember2026-09-30 0001038277us-gaap:NonrelatedPartyMember2025-12-31 0001038277us-gaap:RelatedPartyMember2026-09-30 0001038277us-gaap:RelatedPartyMember2025-12-31 iso4217:USDxbrli:shares 00010382772026-07-012026-09-30 00010382772025-07-012025-09-30 00010382772025-01-012025-09-30 00010382772024-12-31 00010382772025-09-30 0001038277inis:ConversionOfInstallmentsInNotePayableToStockMember2026-01-012026-09-30 0001038277inis:ConversionOfInstallmentsInNotePayableToStockMember2025-01-012025-09-30 0001038277inis:PropertyAcquisitionMember2026-01-012026-09-30 0001038277inis:PropertyAcquisitionMember2025-01-012025-09-30 0001038277inis:ConversionOfAccruedInterestToStockMember2026-01-012026-09-30 0001038277inis:ConversionOfAccruedInterestToStockMember2025-01-012025-09-30 0001038277us-gaap:CommonStockMember2025-12-31 0001038277us-gaap:AdditionalPaidInCapitalMember2025-12-31 0001038277us-gaap:RetainedEarningsMember2025-12-31 0001038277us-gaap:CommonStockMember2026-01-012026-09-30 0001038277us-gaap:AdditionalPaidInCapitalMember2026-01-012026-09-30 0001038277us-gaap:RetainedEarningsMember2026-01-012026-09-30 0001038277us-gaap:CommonStockMember2026-09-30 0001038277us-gaap:AdditionalPaidInCapitalMember2026-09-30 0001038277us-gaap:RetainedEarningsMember2026-09-30 0001038277us-gaap:CommonStockMember2026-06-30 0001038277us-gaap:AdditionalPaidInCapitalMember2026-06-30 0001038277us-gaap:RetainedEarningsMember2026-06-30 00010382772026-06-30 0001038277us-gaap:CommonStockMember2026-07-012026-09-30 0001038277us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-30 0001038277us-gaap:RetainedEarningsMember2026-07-012026-09-30 0001038277us-gaap:CommonStockMember2024-12-31 0001038277us-gaap:AdditionalPaidInCapitalMember2024-12-31 0001038277us-gaap:RetainedEarningsMember2024-12-31 0001038277us-gaap:CommonStockMember2025-01-012025-09-30 0001038277us-gaap:AdditionalPaidInCapitalMember2025-01-012025-09-30 0001038277us-gaap:RetainedEarningsMember2025-01-012025-09-30 0001038277us-gaap:CommonStockMember2025-09-30 0001038277us-gaap:AdditionalPaidInCapitalMember2025-09-30 0001038277us-gaap:RetainedEarningsMember2025-09-30 0001038277us-gaap:CommonStockMember2025-06-30 0001038277us-gaap:AdditionalPaidInCapitalMember2025-06-30 0001038277us-gaap:RetainedEarningsMember2025-06-30 00010382772025-06-30 0001038277us-gaap:CommonStockMember2025-07-012025-09-30 0001038277us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-30 0001038277us-gaap:RetainedEarningsMember2025-07-012025-09-30 xbrli:pure 00010382772026-01-012026-06-30 utr:Y 0001038277inis:NrcLicenseForTheDeconversionFacilityMember2026-01-012026-09-30 thunderdome:item 00010382772026-09-282026-09-28 00010382772026-09-28 0001038277us-gaap:RevolvingCreditFacilityMemberinis:BankOfCommerceMemberus-gaap:SubsequentEventMember2026-10-31 0001038277us-gaap:EmployeeStockOptionMember2026-07-012026-09-30 0001038277us-gaap:EmployeeStockOptionMember2026-01-012026-09-30 0001038277us-gaap:RestrictedStockUnitsRSUMember2026-07-012026-09-30 0001038277us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-09-30 0001038277us-gaap:SeriesCPreferredStockMember2026-07-012026-09-30 0001038277us-gaap:SeriesCPreferredStockMember2026-01-012026-09-30 0001038277us-gaap:EmployeeStockOptionMember2025-07-012025-09-30 0001038277us-gaap:EmployeeStockOptionMember2025-01-012025-09-30 0001038277us-gaap:RestrictedStockUnitsRSUMember2025-07-012025-09-30 0001038277us-gaap:RestrictedStockUnitsRSUMember2025-01-012025-09-30 0001038277us-gaap:SeriesCPreferredStockMember2025-07-012025-09-30 0001038277us-gaap:SeriesCPreferredStockMember2025-01-012025-09-30 0001038277us-gaap:RestrictedStockUnitsRSUMember2026-09-30 0001038277us-gaap:RestrictedStockUnitsRSUMember2025-09-30 0001038277us-gaap:SeriesCPreferredStockMember2026-09-30 0001038277us-gaap:SeriesCPreferredStockMember2025-09-30 0001038277inis:EmployeeStockPurchasePlanMember2026-01-012026-09-30 0001038277inis:EmployeeStockPurchasePlanMember2025-01-012025-09-30 0001038277inis:EmployeeStockPurchasePlanMember2026-09-30 0001038277us-gaap:EmployeeStockOptionMemberinis:The2015IncentivePlanMember2026-09-30 0001038277us-gaap:RestrictedStockUnitsRSUMemberinis:The2015IncentivePlanMember2026-09-30 0001038277inis:The2026IncentivePlanMember2026-07-16 00010382772025-01-012025-12-31 0001038277srt:WeightedAverageMember2026-09-30 0001038277us-gaap:EmployeeStockOptionMember2026-09-30 0001038277us-gaap:EmployeeStockOptionMember2026-01-012026-09-30 0001038277us-gaap:EmployeeStockOptionMember2025-01-012025-09-30 0001038277us-gaap:RestrictedStockUnitsRSUMember2025-12-31 0001038277us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-09-30 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2025-10-102025-10-10 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2025-10-102025-10-10 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2025-10-10 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2025-10-102025-10-10 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2025-10-10 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2025-10-102025-10-10 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2025-10-10 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMemberinis:SharebasedPaymentArrangementTrancheFourMember2025-10-102025-10-10 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMemberinis:SharebasedPaymentArrangementTrancheFourMember2025-10-10 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMemberinis:SharebasedPaymentArrangementTrancheFiveMember2025-10-102025-10-10 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMemberinis:SharebasedPaymentArrangementTrancheFiveMember2025-10-10 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2025-10-10 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMembersrt:ChiefExecutiveOfficerMember2025-10-102025-10-10 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMembersrt:ChiefExecutiveOfficerMember2025-10-102025-10-10 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2026-07-012026-09-30 00010382772026-01-012026-03-31 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2026-01-012026-03-31 0001038277us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2026-01-012026-09-30 0001038277us-gaap:SeriesCPreferredStockMember2026-01-012026-09-30 0001038277us-gaap:SeriesCPreferredStockMember2025-01-012025-09-30 0001038277us-gaap:SeriesCPreferredStockMembersrt:ScenarioForecastMember2026-12-31 0001038277inis:The2013PromissoryNoteMemberinis:MajorShareholdersMember2013-12-012013-12-31 0001038277inis:The2013PromissoryNoteMemberinis:MajorShareholdersMember2013-12-31 0001038277inis:The2013PromissoryNoteMemberinis:MajorShareholdersMember2026-06-30 0001038277inis:The2013PromissoryNoteMemberinis:MajorShareholdersMember2026-06-012026-06-30 0001038277inis:The2013PromissoryNoteMemberinis:MajorShareholdersMember2026-09-30 0001038277inis:The2018PromissoryNoteMemberinis:ChiefExecutiveOfficerAndChairmanOfTheBoardMember2018-04-012018-04-30 0001038277inis:The2018PromissoryNoteMemberinis:ChiefExecutiveOfficerAndChairmanOfTheBoardMember2018-04-30 0001038277inis:The2018PromissoryNoteMemberinis:ChiefExecutiveOfficerAndChairmanOfTheBoardMember2026-06-30 0001038277inis:The2018PromissoryNoteMemberinis:ChiefExecutiveOfficerAndChairmanOfTheBoardMember2026-06-012026-06-30 0001038277inis:The2018PromissoryNoteMemberinis:ChiefExecutiveOfficerAndChairmanOfTheBoardMember2026-09-30 0001038277inis:The2019PromissoryNoteMemberinis:MajorShareholdersMember2019-12-20 0001038277inis:The2019PromissoryNoteMemberinis:MajorShareholdersMember2026-06-30 0001038277inis:The2019PromissoryNoteMemberinis:MajorShareholdersMember2026-06-012026-06-30 0001038277inis:The2019PromissoryNoteMemberinis:MajorShareholdersMember2026-09-30 0001038277inis:The2026PromissoryNoteMemberinis:KershnerGrossoCoMember2026-06-30 0001038277inis:The2026PromissoryNoteMemberinis:KershnerGrossoCoMember2026-06-012026-06-30 0001038277inis:The2026PromissoryNoteMemberinis:KershnerGrossoCoMember2026-09-30 0001038277inis:SecondPromissoryAgreementWithAmiciMember2023-06-30 0001038277inis:SecondPromissoryAgreementWithAmiciMember2023-06-012023-06-30 0001038277inis:ConversionOfAmiciDebtNoteIntoCommonStockMember2023-06-012023-06-30 0001038277inis:PromissoryAgreementWithAMICIMember2023-06-30 0001038277inis:PromissoryAgreementWithAMICIMember2023-06-012023-06-30 0001038277inis:PromissoryAgreementWithAMICIMember2026-09-30 0001038277us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-09-30 0001038277us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-09-30 0001038277us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberinis:ThreeCustomersMember2026-01-012026-09-30 0001038277us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberinis:ThreeCustomersMember2025-01-012025-09-30 0001038277us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberinis:OneCustomerMemberinis:TheranosticsProductsMember2026-01-012026-09-30 0001038277us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberinis:OneCustomerMemberinis:TheranosticsProductsMember2025-01-012025-09-30 0001038277us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberinis:TheranosticsProductsMember2026-01-012026-06-30 0001038277us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberinis:TheranosticsProductsMember2025-01-012025-09-30 0001038277inis:ContractWithTheDoeForTheIrradiationOfCobaltTargetsMember2014-10-022014-10-02 0001038277inis:ContractWithTheDoeForTheIrradiationOfCobaltTargetsMember2014-10-02 0001038277inis:ShortageOfRawMaterialsMember2025-12-31 0001038277us-gaap:AssetPledgedAsCollateralMemberus-gaap:SuretyBondMember2026-09-30 0001038277inis:LeaseAgreementForSecondFacilityMember2025-01-31 0001038277inis:LeaseAgreementForSecondFacilityMember2025-01-012025-01-31 0001038277us-gaap:OperatingSegmentsMemberinis:TheranosticsProductsMember2026-07-012026-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:TheranosticsProductsMember2025-07-012025-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:TheranosticsProductsMember2026-01-012026-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:TheranosticsProductsMember2025-01-012025-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:CobaltProductsMember2026-07-012026-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:CobaltProductsMember2025-07-012025-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:CobaltProductsMember2026-01-012026-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:CobaltProductsMember2025-01-012025-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:CalibrationReferenceProductsMember2026-07-012026-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:CalibrationReferenceProductsMember2025-07-012025-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:CalibrationReferenceProductsMember2026-01-012026-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:CalibrationReferenceProductsMember2025-01-012025-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:MedicalDeviceProductsMember2026-07-012026-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:MedicalDeviceProductsMember2025-07-012025-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:MedicalDeviceProductsMember2026-01-012026-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:MedicalDeviceProductsMember2025-01-012025-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:FluorineProductsMember2026-07-012026-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:FluorineProductsMember2025-07-012025-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:FluorineProductsMember2026-01-012026-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:FluorineProductsMember2025-01-012025-09-30 0001038277us-gaap:OperatingSegmentsMember2026-07-012026-09-30 0001038277us-gaap:OperatingSegmentsMember2025-07-012025-09-30 0001038277us-gaap:OperatingSegmentsMember2026-01-012026-09-30 0001038277us-gaap:OperatingSegmentsMember2025-01-012025-09-30 0001038277us-gaap:CorporateNonSegmentMember2026-07-012026-09-30 0001038277us-gaap:CorporateNonSegmentMember2025-07-012025-09-30 0001038277us-gaap:CorporateNonSegmentMember2026-01-012026-09-30 0001038277us-gaap:CorporateNonSegmentMember2025-01-012025-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:TheranosticsProductsMember2026-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:TheranosticsProductsMember2025-12-31 0001038277us-gaap:OperatingSegmentsMemberinis:CobaltProductsMember2026-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:CobaltProductsMember2025-12-31 0001038277us-gaap:OperatingSegmentsMemberinis:CalibrationReferenceProductsMember2026-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:CalibrationReferenceProductsMember2025-12-31 0001038277us-gaap:OperatingSegmentsMemberinis:MedicalDeviceProductsMember2026-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:MedicalDeviceProductsMember2025-12-31 0001038277us-gaap:OperatingSegmentsMemberinis:FluorineProductsMember2026-09-30 0001038277us-gaap:OperatingSegmentsMemberinis:FluorineProductsMember2025-12-31 0001038277us-gaap:OperatingSegmentsMember2026-09-30 0001038277us-gaap:OperatingSegmentsMember2025-12-31 0001038277us-gaap:CorporateNonSegmentMember2026-09-30 0001038277us-gaap:CorporateNonSegmentMember2025-12-31
 

 

Table of Contents

 



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

 

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________ to _______________

 

Commission file number:

000-22923

 

RADNOSTIX INC.

(Exact name of registrant as specified in its charter)

 

Texas

 

74-2763837

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer Identification No.)

 

4137 Commerce Circle

Idaho Falls, Idaho, 83401

(Address of principal executive offices, including zip code)

 

(208) 524-5300

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☒

Smaller reporting company ☒

  
 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

 

As of November 16, 2026, the number of shares of common stock, $0.01 par value, outstanding was 542,145,510. 

 

 

1

 

 

RADNOSTIX INC.

FORM 10-Q

For The Quarter Ended September 30, 2026

 

TABLE OF CONTENTS

 

   

Page No.

PART I – FINANCIAL INFORMATION

 
     

Item 1.

Financial Statements

 
 

Unaudited Condensed Consolidated Balance Sheets at September 30, 2026 and December 31, 2025

3

 

Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2026 and 2025

4

 

Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025

5

 

Unaudited Condensed Consolidated Statements of Stockholder’s (Deficit) Equity for the Three and Nine Months Ended September 30, 2026 and 2025

 

6

 

Notes to Unaudited Condensed Consolidated Financial Statements

8

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

19

Item 4.

Controls and Procedures

30

     

PART II – OTHER INFORMATION

 
     

Item 1.

Legal Proceedings

30

Item 1A.

Risk Factors

31

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

31

Item 5. Other Information 31

Item 6.

Exhibits

32

Signatures

33

 

2

 

 

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

 

RADNOSTIX INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

 

  

September 30,

  

December 31,

 
  

2026

  

2025

 
  

(unaudited)

    

Assets

        

Current assets

        

Cash and cash equivalents

 $711,288  $1,695,158 

Accounts receivable, net

  1,446,691   1,418,235 

Inventories

  653,440   875,449 

Prepaids and other current assets

  175,673   636,491 

Total current assets

  2,987,092   4,625,333 
         

Long-term assets

        

Restricted cash

  1,532,733   1,492,227 

Property, plant and equipment, net

  4,205,821   3,689,895 

Capitalized lease disposal costs, net

  553,228   590,110 

Operating lease right-of-use asset

  2,696,637   2,846,143 

Goodwill

  1,384,255   1,384,255 

Patents and other intangibles, net

  3,495,177   3,208,669 

Total long-term assets

  13,867,851   13,211,299 

Total assets

 $16,854,943  $17,836,632 
         

Liabilities and Stockholders' Equity

        

Current liabilities

        

Accounts payable

 $1,829,796  $1,530,869 

Accrued liabilities

  1,933,874   1,704,431 

Unearned revenue

  320,131   388,931 

Current portion of operating lease right-of-use liability

  198,747   186,986 

Current installments of notes payable

  87,782   162,715 

Total current liabilities

  4,370,330   3,973,932 
         

Long-term liabilities

        

Related party notes payable

  2,120,000   1,620,000 

Notes payable, net of current portion

  129,679   148,981 

Asset retirement obligation

  1,676,023   1,618,467 

Operating lease right-of-use liability, net of current portion

  2,568,690   2,719,505 

Mandatorily redeemable convertible preferred stock

  4,063,000   4,063,000 

Total long-term liabilities

  10,557,392   10,169,953 

Total liabilities

  14,927,722   14,143,885 
         

Commitments and contingencies (see Note 7)

          
         

Stockholders' equity

        

Common stock, $0.01 par value; 750,000,000 shares authorized; 542,145,510 and 528,209,538 shares issued and outstanding, respectively

  5,421,455   5,282,095 

Additional paid in capital

  127,807,378   126,639,939 

Accumulated deficit

  (131,301,612)  (128,229,287)

Total equity

  1,927,221   3,692,747 

Total liabilities and stockholders' equity

 $16,854,943  $17,836,632 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

3

 

 

RADNOSTIX INC. AND SUBSIDIARIES

Unaudited Condensed Consolidated Statements of Operations

 

  

Three months ended September 30,

  

Nine months ended September 30,

 
  

2026

  

2025

  

2026

  

2025

 
                 

Sale of product

 $2,571,035  $3,277,816  $7,621,744  $10,172,036 

Cost of product

  1,056,820   1,337,797   3,597,346   4,058,421 

Gross profit

  1,514,215   1,940,019   4,024,398   6,113,615 
                 

Operating costs and expenses:

                

Salaries and contract labor

  1,175,732   1,160,434   3,654,251   3,368,592 

General, administrative, and consulting

  958,275   821,588   2,870,318   2,777,519 

Research and development

  163,247   139,411   427,149   348,775 

Total operating expenses

  2,297,254   2,121,433   6,951,718   6,494,886 
                 

Net operating loss

  (783,039)  (181,414)  (2,927,320)  (381,271)
                 

Other income (expense):

                

Other income

  12,974   44,114   67,270   96,558 

Interest income

  17,667   19,984   46,448   60,576 

Interest expense

  (89,844)  (86,285)  (258,723)  (252,943)

Total other expense

  (59,203)  (22,187)  (145,005)  (95,809)

Net loss

 $(842,242) $(203,601) $(3,072,325) $(477,080)
                 

Net loss per common share - basic:

 $—  $—  $(0.01) $— 

Net loss per common share - diluted:

 $—  $—  $(0.01) $— 
                 

Weighted average common shares outstanding - basic

  531,418,649   528,088,472   529,664,465   526,568,064 

Weighted average common shares outstanding - diluted

  531,418,649   528,088,472   529,664,465   526,568,064 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

4

 

 

RADNOSTIX INC. AND SUBSIDIARIES

Unaudited Condensed Consolidated Statements of Cash Flows

 

  

Nine months ended September 30,

 
  

2026

  

2025

 

Cash flows from operating activities

        

Net loss

 $(3,072,325) $(477,080)

Adjustments to reconcile net loss to net cash (used in) provided by operating activities

        

Depreciation and amortization

  316,047   299,698 

Accretion of obligation for lease disposal costs

  57,556   54,936 

Equity based compensation

  482,053   95,364 

Bad Debt Expense

  20,887   — 

Right-of-use asset changes, net

  10,452   (3,358)

Changes in operating assets and liabilities:

        

Accounts receivable

  (49,343)  (449,427)

Inventories

  283,562   (228,778)

Prepaids and other current assets

  310,818   392,200 

Accounts payable and accrued liabilities

  576,550   555,237 

Unearned revenues

  (68,800)  (28,749)

Net cash (used in) provided by operating activities

  (1,132,543)  210,043 
         

Cash flows from investing activities:

        

Purchase of property, plant and equipment

  (205,570)  (254,391)

Net cash used in investing activities

  (205,570)  (254,391)
         

Cash flows from financing activities:

        

Proceeds from sale of stock and exercise of options and warrants

  26,566   14,883 

Proceeds from the issuance of notes payable

  500,000   45,515 

Principal payments on notes payable

  (131,817)  (264,050)

Net cash provided by (used in) financing activities

  394,749   (203,652)
         

Net decrease in cash, cash equivalents, and restricted cash

  (943,364)  (248,000)

Cash, cash equivalents, and restricted cash at beginning of period

  3,187,385   3,377,233 

Cash, cash equivalents, and restricted cash at end of period

 $2,244,021  $3,129,233 
         

Supplemental disclosure of cash flow activities:

        

Cash paid for interest

 $47,431  $160,973 

Cash paid for income taxes

 $6,140  $66 
         

Supplemental disclosure of noncash financing and investing transactions

        

Decrease in current installments of notes payable for issuance of stock

 $—  $25,000 

Property acquired in exchange for issuance of stock

 $750,000  $— 

Property Acquired in exchange for a Notes Payable

 $37,582  $— 

Increase in operating lease right-of-use asset and right-of-use liability for new lease

 $—  $830,720 

Decrease in accrued interest and increase in equity for conversion of dividends to stock

 $48,180  $90,660 

 

Reconciliation of cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows is presented in the table below:                

 

  

September 30,

  

September 30,

 
  

2026

  

2025

 

Cash and cash equivalents

 $711,288  $1,651,548 

Restricted cash included in long-term assets

  1,532,733   1,477,685 

Total cash, cash equivalents, and restricted cash shown in statement of cash flows

 $2,244,021  $3,129,233 

 

See accompanying notes to unaudited condensed consolidated financial statements.

 

5

 

 

RADNOSTIX INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Stockholders' (Deficit) Equity

Three and Nine Months Ended September 30, 2026

(Unaudited)

 

  

Common stock

             
          

Additional

         
  

Shares

  

Common

  

Paid-in

  

Accumulated

  

Total

 
  

Outstanding

  

Stock

  

Capital

  

Deficit

  

(Deficit) Equity

 

Balance, January 1, 2026

  528,209,538  $5,282,095  $126,639,939  $(128,229,287) $3,692,747 

Shares issued under employee stock purchase plan

  496,086   4,960   21,606   —   26,566 

Stock in lieu of dividends on convertible preferred C

  573,570   5,736   42,444   —   48,180 

Shares issued for exercise of employee stock options

  23,851   239   (239)  —   — 

Shares issued to acquire property

  12,842,465   128,425   621,575      750,000 

Stock based compensation

  —   —   482,053   —   482,053 

Net loss

  —   —   —   (3,072,325)  (3,072,325)

Balance, September 30, 2026

  542,145,510  $5,421,455  $127,807,378  $(131,301,612) $1,927,221 

 

   

Common stock

                         
                   

Additional

                 
   

Shares

   

Common

   

Paid-in

   

Accumulated

   

Total

 
   

Outstanding

   

Stock

   

Capital

   

Deficit

   

(Deficit) Equity

 

Balance, July 1, 2026

    529,154,204     $ 5,291,542     $ 127,060,085     $ (130,459,370 )   $ 1,892,257  

Shares issued under employee stock purchase plan

    148,841       1,488       7,368       —       8,856  

Shares issued to acquire property

    12,842,465       128,425       621,575             750,000  

Stock based compensation

    —       —       118,350       —       118,350  

Net loss

    —       —       —       (842,242 )     (842,242 )

Balance, September 30, 2026

    542,145,510     $ 5,421,455     $ 127,807,378     $ (131,301,612 )   $ 1,927,221  

 

6

 

RADNOSTIX INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Stockholders' (Deficit) Equity

Three and Nine Months Ended September 30, 2025

(Unaudited)

 

   

Common stock

                         
                   

Additional

                 
   

Shares

   

Common

   

Paid-in

   

Accumulated

   

Total

 
   

Outstanding

   

Stock

   

Capital

   

Deficit

   

(Deficit) Equity

 

Balance, January 1, 2025

    523,553,435     $ 5,235,534     $ 126,432,759     $ (127,321,285 )   $ 4,347,008  

Shares issued under employee stock purchase plan

    521,102       5,211       9,672       —       14,883  

Stock in lieu of dividends on convertible preferred C

    1,743,457       17,434       73,226       —       90,660  

Stock for Amici

    312,500       3,125       21,875       —       25,000  

Shares issued for issuance of RSUs

    1,566,771       15,668       (15,668 )     —       —  

Stock based compensation

    406,840       4,069       91,295       —       95,364  

Net loss

    —       —       —       (477,080 )     (477,080 )

Balance, September 30, 2025

    528,104,105     $ 5,281,041     $ 126,613,159     $ (127,798,365 )   $ 4,095,835  

 

   

Common stock

                         
                   

Additional

                 
   

Shares

   

Common

   

Paid-in

   

Accumulated

   

Total

 
   

Outstanding

   

Stock

   

Capital

   

Deficit

   

(Deficit) Equity

 

Balance, July 1, 2025

    528,010,308     $ 5,280,103     $ 126,580,543     $ (127,594,764 )   $ 4,265,882  

Shares issued under employee stock purchase plan

    93,797       938       3,048       —       3,986  

Stock based compensation

    —       —       29,568       —       29,568  

Net loss

    —       —       —       (203,601 )     (203,601 )

Balance, September 30, 2025

    528,104,105     $ 5,281,041     $ 126,613,159     $ (127,798,365 )   $ 4,095,835  

 

See accompanying notes to the unaudited condensed consolidated financial statements.

 

7

 

RADNOSTIX INC. AND SUBSIDIARIES

Notes to Unaudited Condensed Consolidated Financial Statements

September 30, 2026

 

 

(1)       The Company and Basis of Presentation

 

Radnostix Inc. (RNX) was incorporated in Texas in November 1995. The accompanying unaudited condensed consolidated financial statements are presented in conformity with accounting principles generally accepted in the United States of America (GAAP) and include all operations and balances of RNX and its wholly-owned subsidiaries, including RadQual, LLC, an Idaho limited liability company (RadQual); TI Services, LLC, an Ohio limited liability company (TI Services); RadVent, LLC, an Idaho limited liability company; International Isotopes Idaho Inc., a Texas corporation; International Isotopes Fluorine Products, Inc., an Idaho corporation; and International Isotopes Transportation Services, Inc., an Idaho corporation. RNX, and its wholly-owned subsidiaries are collectively referred to herein as the “Company,” “we,” “our” or “us.”

 

Nature of Operations – The Company manufactures a wide range of radioisotope-focused products used in variety of medical and industrial applications. The Company's products include a full range of nuclear medicine calibration and reference standards, a wide range of products, including cobalt teletherapy sources, and an FDA-approved radiopharmaceutical drug product. The Company also holds several patents for a fluorine extraction process that would be used in conjunction with a proposed commercial depleted uranium de-conversion facility which would be located in Lea County, New Mexico (the “De-Conversion Facility”). For 2026, the Company’s business consists of five major business segments: Theranostics Products, Cobalt Products, Calibration & Reference Products (previously called Nuclear Medicine Standards), Medical Devices, and Fluorine Products. The Company’s headquarters and all operations, with the exception of TI Services, are located in Idaho Falls, Idaho.

 

With the exception of certain unique products, the Company’s normal operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company’s operating cycle for those products could be considered two to three years. Accordingly, preliminary payments received on cobalt contracts, where shipment will not take place for greater than one year, have been recorded as unearned revenue and, depending upon estimated ship dates, classified under either current or long-term liabilities on the Company’s condensed consolidated balance sheets. These unearned revenues are being recognized as revenue in the periods during which the cobalt shipments take place. All assets expected to be realized in cash or sold during the normal operating cycle of business are classified as current assets.

 

Principles of Consolidation – The accompanying unaudited condensed consolidated financial statements are presented in conformity with GAAP and include all operations and balances of RNX and its wholly-owned subsidiaries including RadQual and TI Services. See Note 4 “Investment and Business Consolidation” for additional information. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Interim Financial Information – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). Accordingly, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments and reclassifications considered necessary in order to make the financial statements not misleading and for a fair and comparable presentation have been included and are of a normal recurring nature. Operating results for the three and nine months ended September 30, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026 or any future periods. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 31, 2026.

 

Recent Accounting Pronouncements

 

In November 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2024‑03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220‑40). This ASU requires entities to disaggregate certain costs and expenses within relevant income statement captions, including disclosures related to employee compensation, depreciation, amortization, and other expense categories. The ASU is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that adoption of this ASU will have on its consolidated financial statements and related disclosures.

 

8

 
 

(2)       Current Developments and Liquidity

 

Business Condition – Since inception, the Company has incurred substantial losses. During the nine months ended September 30, 2026, the Company reported a net loss of $3,072,325 and net cash used in operating activities of $1,132,543. During the nine months ended September 30, 2025, the Company reported net loss of $477,080 and net cash provided by operating activities of $210,043.

 

During the three and nine months ended September 30, 2026, the Company (a) continued its focus on its four core business segments which consist of its Theranostics Products (previously called Radiochemical Products), Calibration & Reference Products (previously called Nuclear Medicine Standards), Cobalt Products, and the start-up of its Medical Device segment, which includes assets purchased from AMICI, Inc. (AMICI) in 2023, investing in the development of an EasyFill Iodine Encapsulation System, and development of the radiation sensing assets purchased from Lucerno Dynamics, LLC (Lucerno) on June 25, 2026.

 

The Company holds a Nuclear Regulatory Commission (NRC) construction and operating license for the depleted uranium facility in, as well as the property agreement with, Lea County, New Mexico, where the plant is intended to be constructed. The NRC license for the de-conversion facility is a forty (40) year operating license and is the first commercial license of this type issued in the United States. 

 

On September 28, 2026, the Company entered into an Asset Purchase Agreement to sell all the Company's assets related to the Fluorine Products segment and the Planned Uranium De-Conversion Facility assets (the “DUF6 Sale”) with Nano Nuclear Energy Inc. ("NNE") and HALEU Energy Fuel Inc., a wholly owned subsidiary of the NNE. Under the DUF6 Sale, NNE agreed to acquire all of the assets that are part of the Company's Fluorine Products segment, mainly assets related to the depleted uranium deconversion and fluorine extraction plant previously planned for Lea County, New Mexico. The aggregate consideration for the DUF6 Sale is $13.5 million. Due to signing the Purchase Agreement, $0.5 million of escrowed funds that were being held to grant NNE exclusive negotiating rights were released to the Company in October. At the Closing of the agreement, NNE will pay us an additional $9 million in cash and issue us $4 million of restricted shares of NNE's common stock with the number of shares determined based on the volume-weighted average price of the Common Stock during the period from the tenth trading day before the date of the Purchase Agreement through the trading day before the Closing Date. Closing is subject to customary and other conditions, including NRC approving the transfer from the Company to NNE and NNE acquiring fee simple title or a valid leasehold interest in the project site in Lea County, New Mexico. 

 

In October 2026, the Company entered into a $1.0 million revolving line of credit with Bank of Commerce to provide additional working capital and liquidity. The facility has a 12-month term and bears interest at the prime rate. Borrowings limits under the facility are subject to eligible accounts receivable and inventory and are secured by the Company's accounts receivable, inventory, and equipment.

 

The Company expects that cash from operations, the availability of equity or debt financing, possible asset sales, and its current cash balance will be sufficient to fund operations for the next twelve months. Future liquidity and capital funding requirements will depend on numerous factors, including commercial relationships, technological developments, market factors, available credit, and management of redeemable convertible preferred stock. There is no assurance that additional capital and financing will be available on acceptable terms to the Company or at all.

   

9

 
 

(3)       Net Income (Loss) Per Common Share - Basic and Diluted

 

For the three and nine months ended September 30, 2026, the Company had 24,912,500 stock options outstanding, 40,500,000 restricted stock units outstanding, and 4,063 outstanding shares of Series C redeemable convertible preferred stock (Series C Preferred Stock), each of which were not included in the computation of diluted income (loss) per common share because they would be anti-dilutive.

 

For the three and nine months ended September 30, 2025, the Company had 26,637,500 stock options outstanding, 3,000,000 restricted stock units outstanding, and 4,063 outstanding shares of Series C Preferred Stock, each of which were not included in the computation of diluted income (loss) per common share because they would be anti-dilutive.

 

The table below shows the calculation of diluted shares:

 

  

Three Months Ended

  

Nine Months Ended

 
  

September 30,

  

September 30,

  

September 30,

  

September 30,

 
  

2026

  

2025

  

2026

  

2025

 

Weighted average common shares outstanding - basic

  531,418,649   528,088,472   529,664,465   526,568,064 
                 

Effects of dilutive shares

                

Stock Options

  —   —   —   — 

Series C Preferred Stock

  —   —   —   — 

Weighted average common shares outstanding - diluted

  531,418,649   528,088,472   529,664,465   526,568,064 

 

The table below summarizes common stock equivalents outstanding at September 30, 2026 and September 30, 2025:

 

  

September 30,

 
  

2026

  

2025

 

Stock options

  24,912,500   26,637,500 

Restricted Stock Units

  40,500,000   3,000,000 

Shares of Series C Preferred Stock

  40,630,000   40,630,000 
   106,042,500   70,267,500 

 

10

 
 

(4)       Investment and Business Consolidation

 

In June 2023, the Company acquired several medical devices with related assets and intellectual property rights from AMICI. In January 2025, the parties amended the Asset Purchase Agreement whereby the Company received additional product rights and related assets to make up for a shortfall by AMICI in deliverable assets originally contemplated in the Asset Purchase Agreement. The Company expects to begin commercialization in Q1 2027.

 

On June 3, 2024, the Company entered into a Strategic Development and Distribution Agreement with Alpha Nuclide Inc for the rights to manufacture and distribute the Company’s Theranostics Products and Nuclear Medicine Products in mainland China as part of a 50/50 joint Venture between the Company and Alpha Nuclides. The parties have already begun with the distribution of the Company’s Calibration & Reference Products in China as part of phase I of the strategic alliance, with further planned milestones for the establishment of a joint venture to register the Company’s Calibration & Reference Products with the CFDA for local manufacturing and distribution. The parties intend to manufacture and distribute the products from Alpha Nuclide's Jiaxing facility, which Alpha Nuclides is responsible for establishing. The parties also intend to enter into a supply agreement for raw material isotopes to be supplied from Alpha Nuclide to the Company to be used in the Company’s manufacturing process at the Company’s Idaho Falls, Idaho facility.

 

On August 6, 2024, the Company entered into a joint venture agreement with Phantech LLC to form PhanQual. PhanQual leverages RNX’s and Phantech’s technologies, facilities, experience, and global network to design, manufacture, and distribute sealed sources, including adapting Phantech's patented and cutting-edge fillable calibration source technology, into sealed source calibration devices to better serve the R&D and theranostics community. Additionally, Radnostix globally distributes Phantech’s entire portfolio of fillable sources through RadQual’s global network of distributors. PhanQual’s revenues and operations are running through Radnostix and are included in our Calibration & Reference Products segment.

 

On June 25, 2026 the Company acquired assets from Lucerno Dynamics, LLC related to the Lara System technology platform and the Ellexa Explorer Software, and all related accessories, parts, consumables, equipment, software, regulatory approval, intellectual property, and hardware associated with these systems. These assets are part of our Medical Devices segment. The acquired IP carries additional applications in radiation detection, such as uptake, dosimetry, quantification, and integration into auto-infusion drug delivery systems, which the Company currently plans to explore the feasibility of developing and commercializing such IP.

 

 

(5)       Stockholders’ Equity, Options, and Warrants

 

Employee Stock Purchase Plan

 

The Company has an employee stock purchase plan pursuant to which employees of the Company may participate to purchase shares of common stock at a discount. During the nine months ended September 30, 2026 and 2025, the Company issued 496,086 and 521,102 shares of common stock, respectively, to employees under the employee stock purchase plan for proceeds of $26,566 and $14,883, respectively. As of  September 30, 2026, 713,008 shares of common stock remain available for issuance under the employee stock purchase plan.

 

Stock-Based Compensation Plans

 

2015 Incentive Plan - On July 14, 2025, the Company's 2015 Incentive Plan (the “2015 Plan”) expired. As of  September 30, 2026, there are 24,912,500 outstanding stock options and 3,000,000 outstanding RSUs that were issued under the 2015 Plan.

 

2026 Incentive Plan - On July 16, 2026, the Company's shareholders approved the Radnostix 2026 Incentive Plan (the “2026 Plan”). The 2026 Plan makes available for grant 12,000,000 shares. The 2026 Plan permits the grant of options, stock appreciation rights, restricted stock, restricted stock units, performance awards and other stock- or cash-based awards. The specific terms and conditions of awards, including vesting, performance criteria and settlement, will be determined by the Compensation Committee. The 2026 Plan terminates on July 16, 2036.

 

Employee/Director Grants - The Company accounts for issuances of stock-based compensation to employees by recognizing, as compensation expense, the cost of employee services received in exchange for equity awards. The compensation expense is based on the grant date fair value of the award. Stock compensation expense is recognized over the period during which an employee is required to provide service in exchange for the award (the vesting period).

 

Non-Employee Grants - The Company accounts for its issuances of stock-based compensation to non-employees by recognizing compensation expense based on the grant date fair value of the award. Stock compensation expense is recognized over the vesting period for the award.

 

11

 

Option awards outstanding as of  September 30, 2026, and changes during the nine months ended September 30, 2026, were as follows:

          

Weighted

     
      

Weighted

  

Average

     
      

Average

  

Remaining

  

Aggregate

 

Fixed Options

 

Shares

  

Exercise Price

  

Contractual Life

  

Intrinsic Value

 

Outstanding at December 31, 2025

  26,562,500  $0.05   5.1     

Granted

  —   —         

Exercised

  70,000   0.04         

Expired

  —   —         

Forfeited

  1,580,000   0.08         

Outstanding at September 30, 2026

  24,912,500   0.05   4.4  $434,800 

Exercisable at September 30, 2026

  21,347,500  $0.05   3.9  $353,100 

 

The intrinsic value of outstanding and exercisable shares is based on the closing price of the Company’s common stock on the OTCQB of $0.06 per share on September 30, 2026.

 

As of  September 30, 2026, there was $19,556 of unrecognized compensation expense related to stock options that will be recognized over a weighted-average period of 1.83 years.

 

Total stock-based compensation expense for the nine months ended September 30, 2026 and 2025 was $482,053 and $95,364, respectively.

 

During the nine months ended September 30, 2026, the Company did not grant any additional stock options.

  

Restricted Stock Units outstanding as of  September 30, 2026, and changes during the nine months ended September 30, 2026, were as follows:

 

Non-Vested Restricted Stock Units

 

Number of restricted stock units

  

Weighted average grant-date fair value

 

Outstanding at December 31, 2025

  3,000,000  $0.04 

Granted

  37,500,000  $0.03 

Vested and Exercised

  —     

Forfeited / Cancelled

  —     

Outstanding at September 30, 2026

  40,500,000  $0.03 

 

As of  September 30, 2026, there was $672,447 of unrecognized compensation expense related to Restricted Stock Units ("RSUs") that will be recognized over a weighted-average period of 2.56 years.

 

On October 10, 2025, the Company granted its CEO 37,500,000 RSUs as part of his new executive employment agreement. These RSUs shall vest upon (i) the Company’s share price being at or above the following levels for 60 consecutive calendar days (“Trigger Date”) and (ii) the earlier of (x) the Company having at least three times the necessary tax withholding amount in available cash or (y) six months following the Trigger Date, vesting as follows: 2,500,000 RSUs will vest at a share price of $0.10; 5,000,000 RSUs will vest at a share price of $0.15; 7,500,000 RSUs will vest at a share price of $0.20; 10,000,000 RSUs will vest at a share price of $0.25; and 12,500,000 RSUs will vest at a share price of $0.30. In the event the CEO is terminated by the Company without cause, all unvested RSUs at such time will immediately vest as of the termination date, and if the CEO is serving in good standing and there is a “change of control” (as defined in the respective RSU award agreements), all unvested RSUs will vest immediately prior to said change of control. The RSUs have a fair value of $1,119,238 as estimated on the date of issue using the Monte Carlo simulation model, which incorporates the probability of achieving the market-based vesting conditions. Key assumptions used in the valuation included a risk-free interest rate of 3.6%, expected volatility of 80.65%, expected term of 1.58 to 2.87 years, and a dividend yield of 0%. The Company recognized stock-based compensation expense of $114,783 for these RSUs for the three months ending  September 30, 2026. The Company’s CEO chose to delay his 2026 milestone RSU due to the FDA recall and as of September 30, 2026 the shares of common stock have not been issued.

 

Additionally, during the three months ended March 31, 2026, the Company identified an error related to the accounting for these RSUs. Specifically, compensation expense associated with these awards was not recognized in the Company’s consolidated financial statements for the year ended December 31, 2025. In accordance with ASC 250, Accounting Changes and Error Corrections, the Company evaluated the materiality of the error, both quantitatively and qualitatively, and determined that the impact was not material to the previously issued financial statements for the year ended December 31, 2025, and that correction of the error in the current period is appropriate. As a result, the Company recorded an out-of-period adjustment of approximately $102,441 of stock-based compensation expense during the three months ended March 31, 2026 related to previously unrecorded stock-based compensation expense. The recognition of this expense increased operating expenses and net loss for the current period. The Company has evaluated the impact of this adjustment on prior interim periods and determined that no restatement of previously issued financial statements is required. The Company recognized stock-based compensation expense of $446,791 for these RSUs for the nine months ended September 30, 2026.

 

12

 

Preferred Stock

 

At September 30, 2026, there were 4,063 total shares of the Series C Preferred Stock outstanding. The Series C Preferred Stock are convertible at the option of the investors at any time into shares of the Company's common stock at an initial conversion price equal to $0.10 per share, subject to adjustment. At any time after February 17, 2019, if the volume-weighted average closing price of the Company’s common stock over a period of 90 consecutive trading days is greater than $0.25 per share, the Company may redeem all or any portion of the outstanding Series C Preferred Stock at the original purchase price per share ($1,000) plus any accrued and unpaid dividends, payable in shares of common stock. All outstanding shares of Series C Preferred Stock were to be redeemed by the Company on February 28, 2022 at the original purchase price per share, payable in cash or shares of common stock, at the option of the holder. In February 2022, based on approval of a majority of the Preferred C Holders, the Company extended the redemption date of the Series C Preferred Stock to February 28, 2023. In December 2022, based on approval of a majority of the Preferred C Holders, the Company extended the redemption date of the Series C Preferred Stock to February 28, 2025. In September 2024, based on approval of a majority of the Preferred C Holders, the Company extended the redemption date of the Series C Preferred Stock to February 28, 2027. In May 2026, based on approval of a majority of the Preferred C Holders, the Company extended the redemption date of the Series C Preferred Stock to February 28, 2028. Holders of Series C Preferred Stock do not have any voting rights, except as required by law and in connection with certain events as set forth in the Statement of Designation of the Series C Preferred Stock.

 

During the nine months ended September 30, 2026 and 2025, dividends due to holders of the Series C Preferred Stock totaled $243,780. Some holders of the Series C Preferred Stock elected to settle their dividend payments with shares of the Company’s common stock in lieu of cash. For the nine months ended September 30, 2026 and 2025, the Company issued an aggregate of 573,570 and 1,743,457 shares of common stock in lieu of dividend payments of $48,180 and $90,660, respectively, with dividend payments settled in cash of $39,300 and $153,120, respectively. The remaining balance of $156,300 that is outstanding as of September 30, 2026 will be settled by the end of 2026.

 

(6)        Debt

 

In December 2013, the Company entered into a promissory note agreement with its then Chairman of the Board and one of our major shareholders, pursuant to which we borrowed $500,000 (the 2013 Promissory Note) which has a current maturity date of March 31, 2031. The 2013 Promissory Note is unsecured and bears interest at 6% per annum and was originally due June 30, 2014. According to the terms of the 2013 Promissory Note, at any time, the lenders could settle any or all of the principal and accrued interest with shares of our common stock. Between 2014 and 2024, the 2013 Promissory Note was modified to extend the maturity date five times with the fifth modification extending the maturity date to March 31, 2026. In August 2025, the 2013 Promissory Note was modified again to extend the maturity date to March 31, 2028, with all remaining terms unchanged. On June 30, 2026, the 2013 Promissory Note was modified again to extend the maturity date to March 31, 2031, add a voluntary lender conversion right at $0.07 per share of the Company's common stock, and add a Company forced-conversion right exercisable if the stock trades for (30) consecutive Trading Day at or above a VWAP of $0.12 per share. At September 30, 2026, accrued interest payable on the 2013 Promissory Note was $384,234.

 

In April 2018, the Company borrowed $120,000 from its then Chief Executive Officer and Chairman of the Board pursuant to a promissory note (the 2018 Promissory Note) which has a current maturity date of March 31, 2031. The 2018 Promissory Note accrues interest at 6% per annum, which is payable upon maturity of the 2018 Promissory Note. The 2018 Promissory Note was originally unsecured and originally matured on August 1, 2018. At any time, lenders could settle any or all of the principal and accrued interest with shares of our common stock. Between 2018 and 2024, the 2018 Promissory Note was modified to extend the maturity date six times with the sixth modification extending the maturity date to March 31, 2026. In August 2025, the 2018 Promissory Note was modified to extend the maturity date to March 31, 2028, with all remaining terms unchanged. On June 30, 2026, the 2018 Promissory Note was modified to extend the maturity date to March 31, 2031, add a voluntary lender conversion right at $0.07 per share of the Company's common stock, and add a Company forced-conversion right exercisable if the stock trades for thirty (30) consecutive Trading Day at or above a VWAP of $0.12 per share. At September 30, 2026, accrued interest on the 2018 Promissory Note totaled $60,770.

 

In December 2019 and February 2020, the Company borrowed an aggregate of $1,000,000 from four of the Company’s major shareholders pursuant to a promissory note (the 2019 Promissory Note) which has a current maturity date of March 31, 2031. The 2019 Promissory Note bears an interest rate of 4% annually and was originally due December 31, 2022. According to the terms of the 2019 Promissory Note, at any time, the lenders could settle any or all of the principal and accrued interest with shares of the Company’s common stock based on the average closing price of the Company’s common stock for the 20 days preceding the payment. In December 2022, the 2019 Promissory Note was modified to extend the maturity date to December 31, 2024, with all remaining terms unchanged. In February 2024, the 2019 Promissory Note was modified to extend the maturity date to March 31, 2026, with all remaining terms unchanged. In August 2025, the 2019 Promissory Note was modified to extend the maturity date to March 31, 2028, with all remaining terms unchanged. On June 30, 2026, the 2019 Promissory Note was modified to extend the maturity date to March 31, 2031, add a voluntary lender conversion right at $0.07 per share of the Company's common stock, and add a Company forced-conversion right exercisable if the stock trades for thirty (30) consecutive Trading Day at or above a VWAP of $0.12 per share. At September 30, 2026, the accrued interest on the 2019 Promissory Note totaled $269,130.

 

In June  2026, the Company borrowed $500,000 from Kershner Grosso & Co., which is owned by the Company's Chairman of the Board (the 2026 Promissory Note). 
The 2026 Promissory Note has a maturity date of June 30,  2031 with an interest rate of 5% per annum, and such interest shall be calculated and paid annually on each anniversary date of the Signing Date. For the first two years of the Note, the Company may elect to pay interest either in cash or in kind. However, following the two-year period, interest on the outstanding principal shall be payable only in cash to the Lender. The Lender has the right to convert the Note at any time to shares of Common Stock at a conversion price of $0.07, rounded down to the nearest share. Beginning six months after the Signing Date, the Company may call the outstanding Note, plus accrued interest, for conversion into Common Stock, so long as the volume weighted-average closing price of the Company stock over a 30 day period is greater than $0.12 per share. At September 30, 2026, the accrued interest on the 2026 Promissory Note totaled $6,528.

 

In June 2023, the Company executed an asset purchase agreement with AMICI, Inc. for the purchase of medical devices and related assets and intellectual property rights. In connection with the asset purchase agreement, the Company issued a promissory note to AMICI, Inc. with a principal amount of $558,593. According to the terms of the note, the Company made an initial cash payment of $100,000 into escrow, issued the seller $25,000 in shares of the Company’s common stock, and paid the seller $6,493 in a closing cash reimbursement payment. For the remaining principal balance of the promissory note of $427,100, the Company is required to pay the seller a minimum of $10,000 per month for a period of 45 months. The amount due was not subject to interest until the 25th month after the anniversary of the closing of the transaction. At September 30, 2026, the balance of this promissory note was $37,100. 

 

13

 
 

(7)       Commitments and Contingencies

 

Dependence on Third Parties

 

Sales to the Company’s top three customers for the nine months ended September 30, 2026 and  September 30, 2025 were approximately 27% and 30% of its total gross revenue respectively. The Company is making efforts to reduce its dependency on a small number of customers by expanding both domestic and foreign. Approximately 16% and 18% of the Company's total gross revenue was from sales from a single customer as part of our Theranostics Products segment.

 

The production of Cobalt-60 is dependent upon the U.S. Department of Energy (DOE), and its prime operating contractor, which controls the Advanced Test Reactor (ATR) and laboratory operations at the ATR located outside of Idaho Falls, Idaho. From 2014 to 2024, the Company had a ten-year contract with the DOE for the irradiation of cobalt targets for the production of cobalt-60. The Company was able to purchase cobalt targets as available for a fixed price per target and with an annual 5% escalation in price. The contract term was October 1, 2014, through September 30, 2024. The Company and the DOE continue to work on this supply agreement with amendments. The DOE have informed the Company that they have secured additional feed stock and remain committed to production of cobalt-60, and the Company continues to source cobalt-60 from the DOE through amendments to the existing contract.

 

Sales of our most predominant Theranostics Products are dependent upon a few key suppliers. An interruption in production by any of these individual suppliers could have an immediate negative impact upon Theranostics Products sales until material could be purchased from alternate suppliers including obtaining regulatory approval to use material from alternative suppliers if necessary. During multiple weeks in 2025, the Company experienced low quantities or complete outages for our key raw material supplier which resulted in an estimated $500,000 in lost sales for the year. The Company has secured other suppliers and continues to search for additional means to produce and procure certain critical isotopes.

 

The Calibration & Reference Products sold by the Company are dependent upon certain radioisotopes that are supplied to the Company through agreements with several suppliers. A loss of any of these suppliers could adversely affect operating results by causing a delay in production or a possible loss of sales. Starting in January 2024, there was a continuing global outage of gadolinium-153, a key isotope for the Company's Calibration & Reference Products segment. The outage resulted in lost sales. The Company was able to secure a supply of gadolinium-153 and start selling related products in October 2026. 

 

Contingencies

 

Because all the Company’s business segments involve the handling or use of radioactive material, the Company is required to have an operating license from the NRC and specially trained staff to handle these materials. The Company has amended this operating license numerous times to increase the amount of material permitted within the Company’s facility. Although this license does not currently restrict the volume of business operations performed or projected to be performed in the upcoming year, additional processing capabilities and license amendments could be implemented that would permit the processing of other reactor-produced radioisotopes by the Company. The financial assurance required by the NRC to support this license has been provided for with a surety bond held with Swiss Re Corporate Solutions Premier Insurance Corporation which is supported by a restricted money market account held with Merrill Lynch. At  September 30, 2026, the balance of this account was $1,532,733.

 

14

 
 

(8)      Revenue Recognition

 

Revenue from Product Sales

 

The Company’s revenue consists primarily of distribution of theranostics including sodium iodide I-131 drug product, calibration and reference standards manufactured for use in the nuclear medicine industry, and cobalt source manufacturing. With the exception of certain unique products, the Company’s normal operating cycle is considered to be one year. Due to the time required to produce some cobalt products, the Company’s operating cycle for those products can be two to three years. Accordingly, preliminary payments received on cobalt contracts where shipment has not taken place have been recorded as unearned revenue on the Company’s condensed consolidated balance sheets and classified under current or long-term liabilities, depending upon estimated ship dates. For the period ended December 31, 2025, the Company reported current unearned revenue of $388,931. During the nine months ended September 30, 2026, $77,891 of this unearned revenue was recognized. For the nine months ended September 30, 2026, the Company reported current unearned revenue of $320,131. These unearned revenues will be recognized as revenue in the periods during which the cobalt shipments take place. 

 

Contract Balances

 

The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied.  As of  September 30, 2026, and December 31, 2025, accounts receivable totaled $1,446,691 and $1,418,235, respectively.  For the nine months ended September 30, 2026, the Company recorded an Allowance for Doubtful Accounts of $13,000, but did not incur material impairment losses with respect to its receivables.

 

 

(9)      Leases

 

The Company leases office and warehouse space under operating leases. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments under the lease. Operating lease, right-of-use assets, and liabilities are recognized at the lease commencement date based on the present value of lease payments over the reasonably certain lease term. The implicit rates with the Company’s operating leases are generally not determinable and the Company uses its incremental borrowing rate at the lease commencement date to determine the present value of its lease payments. The determination of the Company’s incremental borrowing rate requires judgement. The company determines its incremental borrowing rate for each lease using its then-current borrowing rate. Certain of the Company’s leases include options to extend or terminate the lease. The Company establishes the number of renewal options periods used in determining the operating lease term based upon its assessment at the inception of the operating lease. The option to renew the lease may be automatic, at the option of the Company, or mutually agreed to between the landlord and the Company. Once the facility lease term has begun, the present value of the aggregate future minimum lease payments is recorded as a right-of-use asset. Lease expense is recognized on a straight-line basis over the term of the lease. 

 

In January 2025, the Company entered into a new operating lease agreement for a second facility across the street from its main headquarters. The initial term of the lease is five years, ending December 2029 and includes the option to extend the lease for two additional terms of five years each. The monthly lease rate increases annually by 3% each year. The Company has the right of first refusal on this property that allows it to match any offer to purchase this property. The Company recorded an operating lease right-of-use asset and corresponding operating lease right-of-use liability of $830,720 for this lease based on a life of 15 years and incremental borrowing rate of 6.75%. The Company has finished improvements to the facility and is procuring all necessary equipment for future production and working the necessary financial assurance for licensing, with an expected startup in the first half of 2027.

 

15

 
  

Nine Months Ended September 30,

 
  

2026

  

2025

 

Operating lease costs

 $283,095  $281,121 

Short-term operating lease costs

  16,184   11,187 

Financing lease expense:

        

Amortization of right-of-use assets

  —   — 

Interest on lease liabilities

  —   — 

Total financing lease expense

  —   — 

Total lease expense

 $299,279  $292,308 
         

Right-of-use assets obtained in exchange for new operating lease liabilities

 $—  $830,720 

Right-of-use assets obtained in exchange for new financing lease liabilities

 $—  $— 
         

Weighted-average remaining lease term (years) - operating leases

  10.2   10.7 

Weighted-average remaining lease term (years) - financing leases

  —   — 

Weighted-average discount rate - operating leases

  6.75%  6.75%

Weighted-average discount rate - financing leases

  —   — 

 

The future minimum payments under these operating lease agreements are as follows:

 

  

Operating Leases

  

Financing Leases

 

2026 (excluding the nine-months ended September 30, 2026)

 $94,365  $— 

2027

  380,170   — 

2028

  382,962   — 

2029

  385,838   — 

2030

  388,800   — 

Thereafter

  2,227,956   — 

Total minimum lease obligations

  3,860,091   — 

Less-amounts representing interest

  (1,092,654)  — 

Present value of minimum lease obligations

  2,767,437   — 

Current maturities

  (198,747)  — 

Lease obligations, net of current maturities

 $2,568,690  $— 

 

16

 
 

(10)        Segment Information

 

The Company’s reportable segments are reported in a manner consistent with the way management evaluates the businesses. The results of operations are regularly reviewed by the Company's chief operating decision maker ("CODM"), the Chief Executive Officer. The Company identifies its reportable business segments based on differences in products and services. The accounting policies of the business segments are the same as those described in the summary of significant accounting policies. In order to evaluate each reportable segment's performance, the CODM uses income from operations as a measure of profit and loss. The CODM compares operational performance against management expectations when making decisions regarding allocation of operating and capital resources to each segment.

 

In 2026, the Company has five reportable segments which include: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Device Products, and Fluorine Products. Information regarding the operations and assets of these reportable business segments is contained in the following table:

 

  

Three months ended September 30,

  

Nine months ended September 30,

 

Sale of Product

 

2026

  

2025

  

2026

  

2025

 

Theranostics Products

 $1,706,619  $1,484,284  $4,182,028  $5,176,740 

Cobalt Products

  90,680   766,682   598,089   1,517,147 

Calibration & Reference Products

  737,222   961,093   2,675,043   3,301,673 

Medical Device Products

  36,514   65,757   166,584   176,476 

Fluorine Products

  —   —   —   — 

Total Segments

  2,571,035   3,277,816   7,621,744   10,172,036 

Corporate revenue

  —   —   —   — 

Total Consolidated

 $2,571,035  $3,277,816  $7,621,744  $10,172,036 

 

  

Three months ended September 30,

  

Nine months ended September 30,

 

Depreciation and Amortization

 

2026

  

2025

  

2026

  

2025

 

Theranostics Products

 $12,436  $9,962  $37,308  $28,066 

Cobalt Products

  19,144   16,360   55,111   48,722 

Calibration & Reference Products

  24,280   31,481   94,886   92,841 

Medical Device Products

  —   —   —   — 

Fluorine Products

  28,970   26,095   86,909   78,285 

Total Segments

  84,830   83,898   274,214   247,914 

Corporate depreciation and amortization

  13,944   16,820   41,833   51,784 

Total Consolidated

 $98,774  $100,718  $316,047  $299,698 

 

  

Three months ended September 30,

  

Nine months ended September 30,

 

Segment Income (Loss)

 

2026

  

2025

  

2026

  

2025

 

Theranostics Products

 $667,626  $634,625  $1,247,440  $2,521,006 

Cobalt Products

  (160,566)  245,837   (344,096)  571 

Calibration & Reference Products

  (244,964)  (99,118)  (461,414)  130,058 

Medical Device Products

  (301,101)  (187,615)  (678,776)  (570,589)

Fluorine Products

  (64,457)  (76)  (108,650)  (22,330)

Total Segments

  (103,462)  593,653   (345,496)  2,058,716 

Corporate loss

  (738,780)  (797,254)  (2,726,829)  (2,535,796)

Net Loss

 $(842,242) $(203,601) $(3,072,325) $(477,080)

 

  

Three months ended September 30,

  

Nine months ended September 30,

 

Expenditures for Segment Assets

 

2026

  

2025

  

2026

  

2025

 

Theranostics Products

 $—  $4,046  $49,481  $50,561 

Cobalt Products

  —   —   110,023   12,835 

Calibration & Reference Products

  —   57,449   —   75,663 

Medical Device Products

  —   —   46,066   92,893 

Fluorine Products

  —   —   —   — 

Total Segments

  —   61,495   205,570   231,952 

Corporate purchases

  —   —   —   22,439 

Total Consolidated

 $—  $61,495  $205,570  $254,391 

 

  

September 30,

  

December 31,

 

Segment Assets

 

2026

  

2025

 

Theranostics Products

 $1,160,212  $1,115,238 

Cobalt Products

  214,857   260,960 

Calibration & Reference Products

  2,646,241   2,896,335 

Medical Device Products

  1,637,019   697,503 

Fluorine Products

  4,711,207   4,771,359 

Total Segments

  10,369,536   9,741,395 

Corporate assets

  6,485,407   8,095,237 

Total Consolidated

 $16,854,943  $17,836,632 

 

17

  
 

(11)        Subsequent Events

 

In October 2026 the Company submitted a Type II Drug Master File ("DMF") to the FDA for Sodium Iodide I-131 active pharmaceutical ingredient (“API”). The DMF is intended to provide confidential information regarding the manufacturing and controls for Sodium Iodide I-131 API and to permit authorized parties to reference such information in support of their applicable regulatory submissions to the FDA. The filing of the DMF is part of our contractual agreement to support our customer’s efforts to gain approval of their own New Drug Application (“NDA”). We anticipate a period of FDA review and potential RAIs prior to achieving an approval.

 

In November 2026 the Company received Health Canada approval for the registration of our line geometry sources, which are part of our Calibration & Reference Products. This approval will allow us to commercialize Gd-153 products, among other Calibration & Reference Products. This approval is part of our wider effort to register all of our Calibration & Reference Products with Health Canada.

 

The Company was able to secure a Gd-153 supply for the first time since January of 2024. The Company completed internal testing & validation in October and was able to ship commercial batches of Gd-153 Calibration & Reference Products in November of 2026.

 

In October 2026, the Company entered into a $1.0 million revolving line of credit with Bank of Commerce to provide additional working capital and liquidity. The facility has a 12-month term and bears interest at the prime rate. Borrowings limits under the facility are subject to eligible accounts receivable and inventory and are secured by the Company's accounts receivable, inventory, and equipment.

 

 

18

 
 

ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding industry prospects and future results of operations or financial position, made in this Quarterly Report are forward-looking statements. Words such as “anticipates,” “believes,” “should,” “expects,” “future,” “intends” and similar expressions identify forward-looking statements. Forward-looking statements reflect management’s current expectations, plans or projections, and are inherently uncertain. Actual results could differ materially from management's expectations, plans or projections. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Quarterly Report. Certain risks and uncertainties that could cause our actual results to differ significantly from management’s expectations are described in the risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the Securities and Exchange Commission (SEC) on March 31, 2026 and in the other reports we file with the SEC. These factors describe some but not all of the factors that could cause actual results to differ significantly from management’s expectations. We undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are urged, however, to review the risks and other factors set forth in the reports that we file from time to time with the SEC.

 

BUSINESS OVERVIEW

 

Radnostix Inc. and its wholly-owned subsidiaries (including RadQual, LLC, TI Services, LLC, RadVent, LLC, International Isotopes Idaho Inc., International Isotopes Fluorine Products, Inc., and International Isotopes Transportation Services, Inc.) (collectively, the "Company", "we", "our", or "us") manufacture a full range of nuclear medicine calibration and reference standards, manufacture a range of cobalt products, and distribute sodium iodide I-131 as a generic drug.

 

Our core business consists of five reportable segments which include: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products.

 

-

In our Theranostics Products segment, which is our largest segment by revenue, we produce:

 

 

•

an FDA approved generic sodium iodide I-131 drug product for the treatment of hyperthyroidism and thyroid cancer;

 

 

•

radiochemicals for multiple uses in clinical research and life sciences (including Tb-161 and variations of I-131); and

 

 

•

cGMP Active Pharmaceutical Ingredient (“API”) supply for third party theranostics clients. “cGMP” refers to current Good Manufacturing Practice regulations that are enforced by the FDA for quality and safety control;

 

-

In our Cobalt Products segment, we produce a variety of cobalt-60 products for medical, research and industrial applications. Cobalt-60 is a synthetic radioactive isotope of cobalt that is produced by irradiating the stable isotope cobalt-59;

 

-

In our Calibration & Reference Products segment (formerly referred to as Nuclear Medicine), we produce a wide range of sealed source calibration and reference standards (which are sealed to prevent the release of radioactive materials), that are used in: (i) nuclear pharmacies that specialize in preparing and dispensing radioactive pharmaceuticals for diagnostic imaging and medical treatments, (ii) nuclear medicine imaging clinics and hospitals which administer radioactive pharmaceuticals, (iii) certain laboratories and equipment that require radiation detection, and (iv) industrial settings that use radioactive sources for calibration, testing, and measurement. We also sell bulk isotopes through this segment;

 

-

In our Medical Devices segment, we currently sell various 3rd party products and we are developing our own products for commercial use, including an I-131 encapsulation system, Radvent devices, and the assets acquired from Lucerno Dynamics (the Lara and Ellexa systems).

 

-

Our Fluorine Products segment holds an NRC construction and operating license for the depleted uranium facility in Lea County, New Mexico, where the plant is intended to be constructed. On September 28, 2026, we entered an asset purchase agreement to sell all assets in this segment as described under Fluorine Products below.

 

We believe that we are well positioned to serve the growing radioisotope and radiopharmaceutical market segments.

 

19

 

Theranostics Products. This segment includes the production and distribution of various isotopically pure radiopharmaceuticals, APIs, and radiochemicals for medical, industrial, and research applications. These products are produced by us from radioisotopes supplied by our vendors. We produce and distribute various products in customized volumes, concentrations, chemical formulations, packages, and specifications tailored to meet our FDA specifications or customer and market demands. To our knowledge, our FDA approved generic sodium iodide I-131 drug product is the only generic product of this type manufactured in the U.S. and offers customers an attractive domestic alternative to the single existing foreign commercial drug manufacturer. Additionally, this segment distributes APIs, and radiochemicals from third party suppliers for pre-clinical, industrial, and research applications. According to BCC Research, the theranostics market was valued at $4.3 billion in 2024 and is expected to grow to $12.7 billion by 2029, reflecting a 24% compound annual growth rate.

 

The markets for most radiochemicals is highly competitive. The target markets for these products are customers who (1) incorporate them into finished industrial or medical devices; (2) use radioisotope products in clinical trials for various medical applications with the aim to further process and include the radioisotope products into pharmaceutical products approved by the U.S. FDA for labeled use in therapy or imaging, or (3) include our radioisotope products into their pharmaceutical products approved outside the U.S. for encapsulated and/or labeled use in therapy or imaging. We can ship to all 50 states and internationally. We are deploying a unique product strategy which we believe will make us the go-to API supplier for third party radiopharmaceutical products.

 

We believe that we are well positioned to hold a competitive advantage in the growing theranostics space because of our unique combination of high energy and high activity NRC licensing status that permits handling of high energy and high activity radioisotopes, our compliance with GMP, our FDA licensed operating facility, and experienced and skilled personnel.

 

In October 2026, we submitted a Type II Drug Master File ("DMF") to the FDA for Sodium Iodide I-131 active pharmaceutical ingredient (“API”). The DMF is intended to provide confidential information regarding the manufacturing and controls for Sodium Iodide I-131 API and to permit authorized parties to reference such information in support of their applicable regulatory submissions to the FDA. The filing of the DMF is part of our contractual agreement to support our customer’s efforts to gain approval of their own New Drug Application (“NDA”).

 

Cobalt Products. Our Cobalt Products segment includes the production of various cobalt-60 products and services, including the fabrication of cobalt-60 sealed sources for radiation therapy, various industrial and medical applications, and recycling of expended cobalt-60 sources.

 

We have explored, and intend to continue to explore, opportunities to further develop cobalt-60 and other high-energy and high-activity products and sales on an ongoing basis, including new suppliers of cobalt-60 and the applications of cobalt-60 in radioisotope thermoelectric generators (RTGs). The production, use, transport, and import/export of these products are all heavily regulated by the NRC and DOT, state and local agencies as well as similar regulatory authorities in territories outside of the United States (i.e., EU, China, Australia, Brazil and Argentina), but we have developed a highly experienced staff of technicians, shipping specialists, and supervisors in order to comply with the regulations and to deliver these products in a cost-effective, timely manner.

 

We believe that our domestically manufactured products and service offerings provide us with a competitive edge over other foreign cobalt-60 manufacturers.

 

20

 

Calibration & Reference Products. (formerly known as Nuclear Medicine Standards) The Calibration & Reference Products segment consists of various sealed source calibration and reference products, including our own manufactured products, jointly manufactured products, and third-party products. These products are sold through our RadQual brand for use with SPECT and PET imaging equipment, patient positioning, radiopharmacy and radiopharmaceutical Contract Development and Manufacturing Organization (“CDMO”) lab equipment, pre-clinical imaging equipment, clinical trial or custom geometry applications, and calibration or operational testing of measuring and/or testing equipment. Our Calibration & Reference Products include flood sources, dose calibrator sources, cylinder phantoms, annulus phantoms, rod sources, line sources, flexible and rigid rulers, spot markers, pen point markers, and a host of specialty design items. Our pre-clinical products include distribution of fillable sources from Phantech and pre-clinical sealed sources via our PhanQual joint venture with Phantech. Our Calibration and Reference sources include RadQual products for lab equipment; we also distribute non-medical sealed source calibration and reference standards manufactured by ORANO LEA, who also distributes and uses our products. Our Calibration & Reference Products segment also commercializes bulk isotope sales and shielding and accessories related to our sealed source products.

 

According to the International Atomic Energy Agency’s Medical imAGIng and Nuclear mEdicine global resources database (IMAGINE), as of September 2025, at least 131 countries have SPECT and/or PET imaging cameras, with more than 29,000 installed units in total. These installed cameras use calibration and reference sources on a regular repeat basis, with many of them requiring calibration as part of on-going certification. Most Calibration and Reference Product sales are to U.S. customers. However, in recent years, because of stronger marketing efforts, we have seen an increase in foreign sales. All these products contain radioactive isotopes that decay at a predictable rate. Therefore, customers are required to periodically replace most of these products when they reach the end of their useful lives. The useful life of these products varies depending on the isotope used in manufacture, but in most cases averages eighteen months to two years. The various isotopes used in manufacturing these Calibration & Reference Products are from several sources world-wide, and we are continually working to develop multiple sources of each isotope. In addition to the products themselves, we have developed a line of specialty packaging for the safe transportation and handling of these products.

 

To our knowledge there are a few small regional suppliers internationally and only one major producer of a similar catalog of products in the world that competes directly with us for this broad portfolio of products. Most of the products manufactured by our major competitor are similar in design to our products as these products must meet Original Equipment Manufacturer (“OEM”) dimensional and performance standards. We attempt to differentiate our products through strategic alignment with OEMs, high levels of service, competitive pricing, patent protections, and exclusive arrangements with OEMs.

 

We continue working to expand the number and types of products that are manufactured in this segment, expand the number of jurisdictions where we have regulatory approvals, and expand our qualified suppliers for the raw material used for our products. We plan to eventually manufacture some of our medical products in China through our joint-venture, Radnostix China.

 

Medical Devices. We started the Medical Devices segment in 2024 and many of our products in this segment remain under development. Our Medical Device segment will consist of our own medical devices and the distribution and servicing of third-party products. Our Medical Device segment is currently developing various types of devices, including lab equipment, FDA Class I, and FDA Class II medical devices.

 

As of September 30, 2026, all of our revenue in the Medical Devices segment comes from the sale of third party products.

 

We are currently in development of the EasyFill Iodine Encapsulation System, a robotic lab device to be paired with our Theranostics Products. The EasyFill is still in the developmental stage. We are targeting a Q1 2027 roll out and Q3 2027 commercial ramp up. This will include additional sales of I-131 for our Theranostics segment.

 

We are currently finalizing the development of our RadVent branded products and are expected to begin commercialization in Q1 2027. We acquired assets from AMICI, Inc. in 2023 including manufacturing molds, device registrations, trademarks, and all production rights to several AMICI, Inc. medical device and accessory products for lung ventilation. This includes the Swirler Radioaerosol System and Tru-Fit mouthpiece products. In January 2025, we also received the manufacturing molds, device registrations, trademarks, and all production rights to the AMICI, Inc. line of Xenon System products. The products will be manufactured at various 3rd party contract manufacturers and sold through distributors under the RadVent brand.

 

On June 25, 2026 the Company acquired from Lucerno Dynamics, LLC certain assets related to the Lara System technology platform and the Ellexa Explorer Software and all related accessories, parts, consumables, equipment, software, regulatory approval, intellectual property, and hardware associated with these systems. In addition to revenue from the existing Lara and Ellexa platform, the acquired IP carries additional applications in radiation detection, such as uptake, dosimetry, quantification, and integration into auto-infusion drug delivery systems, which the Company currently plans to explore the feasibility of developing and commercializing such IP. We plan to pivot these assets to be sold under a Lara Detection branding.

 

21

 

Fluorine Products. We established the fluorine products business segment in 2004 to support production and sale of various fluoride gases produced using our Fluorine Extraction Process (“FEP”). FEP was intended to be completed in conjunction with the operation of a proposed depleted uranium, or DUF6, de-conversion facility in Lea County, New Mexico. DUF6 is the waste by-product of uranium enrichment, and any uranium enrichment facility will create very large quantities of DUF6. In October 2012, we received a construction and operating license from the NRC for the planned facility. Changes in the nuclear industry near the end of 2013, however, significantly reduced commercial demand for this type of facility. Therefore, we suspended all further development work on the project, but we have maintained all licenses and permits for the project.

 

On September 28, 2026, we entered into an Asset Purchase Agreement to sell all the Company's assets related to the Fluorine Products segment and the Planned Uranium De-Conversion Facility assets (the “DUF6 Sale”) with Nano Nuclear Energy Inc. ("NNE") and HALEU Energy Fuel Inc., a wholly owned subsidiary of the NNE. Under the DUF6 Sale, NNE agreed to acquire all of the assets that are part of the Company's Fluorine Products segment, mainly assets related to the depleted uranium deconversion and fluorine extraction plant previously planned for Lea County, New Mexico. The aggregate consideration for the DUF6 Sale is $13.5 million. Due to signing the Purchase Agreement, $0.5 million of escrowed funds that were being held to grant NNE exclusive negotiating rights were released to us in October. At the Closing of the agreement, NNE will pay us an additional $9 million in cash and issue us $4 million of restricted shares of NNE's common stock with the number of shares determined based on the volume-weighted average price of the Common Stock during the period from the tenth trading day before the date of the Purchase Agreement through the trading day before the Closing Date. Closing is subject to customary and other conditions, including NRC approving the transfer from the Company to NNE and NNE acquiring fee simple title or a valid leasehold interest in the project site in Lea County, New Mexico. 

 

22

 

RESULTS OF OPERATIONS

 

Three and Nine Months Ended September 30, 2026, Compared to the Three and Nine Months Ended September 30, 2025

 

 

Sale of Product for the three months ended September 30, 2026 was $2,571,035 as compared to $3,277,816 for the same period in 2025, an overall decrease of $706,781, or approximately 22%.

 

Sale of Product for the nine months ended September 30, 2026 was $7,621,744 as compared to $10,172,036 for the same period in 2025, an overall decrease of $2,550,292, or approximately 25%.

 

This decrease in sales for the nine months ended September 30, 2026 , as compared to the same periods in 2025 was the result of lost sales in our Theranostics Products segment due to the effects from two voluntary product recalls during January and February of 2026 as discussed in more detail below and decreased sales in our Cobalt Products segment due to operational shutdown for the rehabilitation of our process hot cells during the three months ended March 31, 2026 and due to delays in several cobalt contracts. For the three months ended September 30, 2026 there was a decrease to sales in our Cobalt Products, Calibration & Reference Products, and Medical Device Products segment partially offset by increased sales in our Theranostics Products segment, as discussed in more detail below.

 

The following table presents a period-to-period comparison of total revenue by segment for the three and nine months ended September 30, 2026 and September 30, 2025:

 

   

Three months ended September 30,

 

Nine Months Ended September 30,

Sale of Product

 

2026

 

2025

 

$ Change

 

% Change

 

2026

 

2025

 

$ Change

 

% Change

Theranostics Products

 

$ 1,706,619

 

$ 1,484,284

 

$ 222,335

 

15%

 

$ 4,182,028

 

$ 5,176,740

 

$ (994,712)

 

(19%)

Cobalt Products

 

$ 90,680

 

766,682

 

(676,002)

 

(88%)

 

598,089

 

1,517,147

 

(919,058)

 

(61%)

Calibration & Reference Products

 

737,222

 

961,093

 

(223,871)

 

(23%)

 

2,675,043

 

3,301,673

 

(626,630)

 

(19%)

Medical Device Products

 

36,514

 

65,757

 

(29,243)

 

(44%)

 

166,584

 

176,476

 

(9,892)

 

(6%)

Fluorine Products

 

—

 

—

 

—

 

—%

 

—

 

—

 

—

 

—%

Total Consolidated Sale of Product

 

$ 2,571,035

 

$ 3,277,816

 

$ (706,781)

 

(22%)

 

$ 7,621,744

 

$ 10,172,036

 

$ (2,550,292)

 

(25%)

 

Cost of product decreased to $1,056,820 for the three months ended September 30, 2026 from $1,337,797 for the same period in 2025. This is a decrease of $280,977, or approximately 21%.

 

Cost of product decreased to $3,597,346 for the nine months ended September 30, 2026 from $4,058,421 for the same period in 2025. This is a decrease of $461,075, or approximately 11%.

 

The decrease in cost of product for the three months and nine months ended September 30, 2026, as compared to the same periods in 2025 was due to decreased sales overall which was partially offset by adjustments for accounting for labor hours beginning in 2026 that increased allocation of labor costs to cost of product. We evaluated and updated our policies for classifying and recording direct labor hours. We believe these updates will better reflect costs allocation for our current operations.

 

Gross profit for the three months ended September 30, 2026 was $1,514,215, compared to $1,940,019 for the same period in 2025. This represents a decrease in gross profit of $425,804, or approximately 22%, compared to the same period in 2025. 

 

Gross profit for the nine months ended September 30, 2026 was $4,024,398, compared to $6,113,615 for the same period in 2025. This represents a decrease in gross profit of $2,089,217, or approximately 34%, compared to the same period in 2025.

 

The decreases in gross profit for the three months and nine months ended September 30, 2026, as compared to the same periods in 2025 is due to decreased sales of product and increases to cost of product.

 

The following table presents cost of product and gross profit data for each of our business segments for the three and nine months ended September 30, 2026 and September 30, 2025:

 

   

For the Three

     

For the Three

     

For the Nine

     

For the Nine

   
   

Months Ended

 

% of

 

Months Ended

 

% of

 

Months Ended

 

% of

 

Months Ended

 

% of

   

September 30,

 

Total Sales

 

September 30,

 

Total Sales

 

September 30,

 

Total Sales

 

September 30,

 

Total Sales

   

2026

 

2026

 

2025

 

2025

 

2026

 

2026

 

2025

 

2025

Total Sale of Product

 

$ 2,571,035

     

$ 3,277,816

     

$ 7,621,744

     

$ 10,172,036

   

Cost of Product

                               

Theranostics Products

 

$ 555,394

 

22%

 

$ 482,414

 

15%

 

$ 1,564,180

 

21%

 

$ 1,492,414

 

15%

Cobalt Products

 

45,689

 

2%

 

283,794

 

9%

 

327,080

 

4%

 

755,393

 

7%

Calibration & Reference Products

 

415,274

 

16%

 

512,156

 

16%

 

1,583,142

 

21%

 

1,656,980

 

16%

Medical Device Products

 

40,463

 

1%

 

59,433

 

2%

 

122,944

 

1%

 

153,634

 

2%

Fluorine Products

 

—

 

—%

 

—

 

—%

 

—

 

0%

 

—

 

—%

Total Cost of Product

 

$ 1,056,820

 

41%

 

$ 1,337,797

 

41%

 

$ 3,597,346

 

47%

 

$ 4,058,421

 

40%

                                 

Gross Profit

 

$ 1,514,215

     

$ 1,940,019

     

$ 4,024,398

     

$ 6,113,615

   

Gross Profit %

 

59%

     

59%

     

53%

     

60%

   

 

23

 

For the three months ended September 30, 2026, total operating costs and expenses in all segments increased approximately 8% to $2,297,254 from $2,121,433 for the same period in 2025. This increase of $175,821 in the three months ended September 30, 2026 was due to increased General, Administrative, and Consulting expenses due to increased professional services and increased license costs, partially offset by decreases in waste expenses for our Cobalt Products segment. Research and Development expenses also increased due to increased development activity in our Medical Device Products segment.

 

For the nine months ended September 30, 2026, total operating costs and expenses in all segments increased approximately 7% to $6,951,718 from $6,494,886 for the same period in 2025. This increase of $456,832 in the nine months ended September 30, 2026 was due to increased General, Administrative, and Consulting expenses for increased professional fees and license costs, Salaries and Contract Labor expenses due to increases in stock-based compensation expense, which included an out-of-period adjustment of $102,441 in Q1 2026, and increased Research and Development expenses due to increased development activity in our Medical Device Products segment. 

 

The following table presents a comparison of total operating expenses for the three and nine months ended September 30, 2026 and 2025:

 

   

Three months ended September 30,

 

Nine Months Ended September 30,

Operating Costs and Expenses:

 

2026

 

2025

 

% change

 

$ change

 

2026

 

2025

 

% change

 

$ change

Salaries and Contract Labor

 

$ 1,175,732

 

$ 1,160,434

 

1%

 

$ 15,298

 

$ 3,654,251

 

$ 3,368,592

 

8%

 

$ 285,659

General, Administrative and Consulting

 

958,275

 

821,588

 

17%

 

136,687

 

2,870,318

 

2,777,519

 

3%

 

92,799

Research and Development

 

163,247

 

139,411

 

17%

 

23,836

 

427,149

 

348,775

 

22%

 

78,374

Total operating expenses

 

$ 2,297,254

 

$ 2,121,433

 

8%

 

$ 175,821

 

$ 6,951,718

 

$ 6,494,886

 

7%

 

$ 456,832

 

Other income was $12,974 for the three months ended September 30, 2026 as compared to other income $44,114 for the same period in 2025. This is a decrease of $31,140, or approximately 71%. Other income was $67,270 for the nine months ended September 30, 2026 as compared to other income $96,558 for the same period in 2025. This is a decrease of $29,288, or approximately 30%. The differences in both the three months and nine months ended September 30, 2026 as compared to the same periods in 2025 were due to timing of extension payments from April 2025 through March 2026 as part of the Fluorine Products Asset Sale.

 

Interest expense for the three months ended September 30, 2026 was $89,844, compared to $86,285 for the same period in 2025. This is an increase of $3,559, or approximately 4%. Interest expense for the nine months ended September 30, 2026 was $258,723, compared to $252,943 for the same period in 2025. This is an increase of $5,780, or approximately 2%. 

 

Interest expense includes dividends accrued on our Series C Preferred Stock. As discussed below, we issued Series C Preferred Stock in February 2017 and May 2017. For the three months ended September 30, 2026 and 2025, we accrued dividends payable of $60,945 for both periods, which have been recorded as interest expense. For the nine months ended September 30, 2026 and 2025 we accrued dividends of $182,835 for both periods. See Note 6 “Debt” to our unaudited consolidated financial statements in this Quarterly Report for additional information about our indebtedness and the associated interest expense.

 

We had a net loss of $842,242 for the three months ended September 30, 2026 compared to net loss of $203,601 for the same period in 2025. This increase in net loss of $638,641 for the quarter was the result of decreased sales in our Cobalt Products segment due to timing of projects, decreased sales in our Calibration & Reference Products and Medical Device Products segments and increased operating expenses. This was partially offset by increased sales in our Theranostics Products segment.

 

We had a net loss of $3,072,325 for the nine months ended September 30, 2026 compared to net loss of $477,080 for the same period in 2025. This increase in net loss of $2,595,245 for the period ended was also the result of lost sales in our Theranostics Products due to the effects from two voluntary product recalls during January and February of 2026 as discussed in more detail below, decreased sales in our Cobalt Products segment due to the rehabilitation of our process hot cells during the period and the delay of some cobalt source projects, and decreased sales in our Calibration & Reference Products and Medical Device Products segments. Additionally, the increase in net loss was due to increased operating expenses resulting from increased Salaries and Contract Labor expenses from increases in stock-based compensation expense, which included an out-of-period adjustment of $102,441, increased General, Administrative, and Consulting expenses from increased professional fees and license costs, and increased Research and Development expenses due to increased development activity in our segments. 

 

24

 

Theranostics Products.

Sales of Theranostics Products for the three months ended September 30, 2026 were $1,706,619, compared to $1,484,284 for the same period in 2025. This is an increase of $222,335, or approximately 15% during the three months ended September 30, 2026.

 

The increased sales during the three months ended September 30, 2026 was due to increased sales of our Generic Sodium Iodide I-131in the period. Starting in July 2026, sales volumes were fully restored, and we even saw increases to our pre-recall sales levels. The recalls and their financial effects are discussed in more detail below. We expect sales to continue to increase over time.

 

Sales of Theranostics Products for the nine months ended September 30, 2026 were $4,182,028, compared to $5,176,740 for the same period in 2025. This is a decrease of $994,712, or approximately 19% during the nine months ended September 30, 2026. 

 

The decreases in sales during the nine months ended September 30, 2026, as compared to the same period in 2025, was largely due to two voluntary recalls: The first was a voluntary Class II recall of our Generic Sodium Iodide I-131 due to the discovery of septum in our finished product vials on January 26, 2026. We had recently been approved by the FDA to implement new septum for our finished products, with this change we discovered the septum did not perform equivalent to our previous testing and validation. The impact from this recall was limited to that first batch and resulted in $60,000 of lost revenue. The second voluntary recall was due to the finished specifications of Dibasic Sodium Phosphate Capsules. On February 19, 2026, the Company, which is a manufacturer of its Generic Sodium Iodide I-131, discovered during an internal review that specific lots of our Dibasic Sodium Phosphate Capsules that may be provided with our Generic Sodium Iodide I-131 kits manufactured between 2022 and 2025 were out of specification for final capsule weight. We initiated a voluntary Class III recall of specific lots of our Dibasic Sodium Phosphate Capsules shipped between August 19, 2024 to February 17, 2026 and a Field Alert Report for the expired lots from 2021 to 2024. We notified affected pharmacies, clinics, and veterinarians of the voluntary recall. We issued customer credits of approximately $50,000 in the first quarter of 2026 related to refunds to certain customers. We wrote off our impaired capsule inventory of approximately $75,000 in the fourth quarter of 2025. We continued to provide Generic Sodium Iodide I-131, which was not impacted. The majority of our customers continued to order this material during the time we had no capsules. For the customers that require capsules with their orders, we lost an estimated $850,000 in revenue during the first two quarters of the year. We were able to restore our capsule inventory at the end of June 2026. Customer volumes returned and sales were normalized in July 2026. Both recalls have been fully executed. All required documentation was submitted to the FDA in June 2026, and we are awaiting formal closeout of the recall. The FDA acknowledged our recall termination request and advised us of a recall termination backlog and has provided no further communication. Our business has not been impacted by the recall beyond the impacts addressed above. 

 

Cost of product for Theranostics Products increased to $555,394 for the three months ended September 30, 2026, as compared to $482,414 for the same period in 2025. This is an increase of $72,980, or approximately 15% and due to increased sales in the period. Cost of product increased to $1,564,180 for the nine months ended September 30, 2026, as compared to $1,492,414 for the same period in 2025. This is an increase of $71,766, or 5%. The increased Cost of Product during the nine months ended September 30, 2026, as compared to the same period in 2025, was the result of adjustments for accounting for labor hours to all segments that began in 2026 that increased the allocation to Cost of Product as discussed above.

 

Gross profit of Theranostics Products for the three months ended September 30, 2026 was $1,151,225, compared to $1,001,870 for the same period in 2025, and gross profit percentage was approximately 67% and 67% for three months ended September 30, 2026 and 2025 respectively. Gross profit for the nine months ended September 30, 2026 was $2,617,848, compared to $3,684,326 for the same period in 2025, and gross profit percentage was approximately 63% and 71% for nine months ended September 30, 2026 and 2025 respectively.

 

Operating expenses for this segment increased to $483,599 for the three months ended September 30, 2026, compared to $367,245 for the same period in 2025. Operating expenses for this segment increased to $1,370,408 for the nine months ended September 30, 2026, compared to $1,163,320 for the same period in 2025. This is an increase in operating expenses of $207,088, or approximately 18%. Increases in operating expenses for the three months and nine months ended September 30, 2026, as compared to the same periods in 2025, were due to increased license and permit expense, increased research and development costs, and increased salary and labor costs. We also incurred operating expenses related to our development and subsequent submission in October 2026 of a Type II Drug Master File ("DMF") to the FDA for Sodium Iodide I-131 active pharmaceutical ingredient (“API”). The DMF is intended to provide confidential information regarding the manufacturing and controls for Sodium Iodide I-131 API and to permit authorized parties to reference such information in support of their applicable regulatory submissions to the FDA. The filing of the DMF is to support our customers efforts to gain approval of a theranostic NDA.

 

For the three months ended September 30, 2026, this segment reported net income of $667,626 as compared to net income of $634,625 for the same period in 2025. This is a increase in net income of $33,001 due to increased sales in the period. For the nine months ended September 30, 2026, this segment reported net income of $1,247,440 as compared to net income of $2,521,006 for the same period in 2025. This is a decrease in net income of $1,273,566. This decrease net income in the Theranostics Products segment for the nine months ended September 30, 2026, as compared to the same period in 2025, was the result of decreased sales due to the effects of the two voluntary recalls and increased operating expenses.

 

25

 

Cobalt Products.

Sales of product in the Cobalt Products segment for the three months ended September 30, 2026 was $90,680, compared to $766,682 for the same period in 2025. This represents a decrease of $676,002, or approximately 88%. Sales of product in the Cobalt Products segment for the nine months ended September 30, 2026 was $598,089, compared to $1,517,147 for the same period in 2025. This represents a decrease of $919,058, or approximately 61%. 

 

The decreased sales for the third quarter were due to delays in large Cobalt contracts, which are awaiting NRC amendments to our registered Sealed Source Devices; these contracts are projected to be executed in the 1st quarter of 2027. The decreases in sales of product for the nine months were partially due shut down of Cobalt-60 manufacturing operations to prepare and repair the window gaskets of both our process hot cells that took place in the first quarter of 2026 that was previously disclosed.

 

Cost of product for the three months ended  September 30, 2026, was $45,689, as compared to $283,794, for the same period in 2025 for a  decrease of  84%. Gross profit for cobalt products for the three months ended  September 30, 2026 was $44,991 compared to  $482,888 for the same period in 2025. This is a  decrease of $437,897, or approximately  91%. Gross profit percentages were  50% and  63% respectively. The  decrease in cost of product was due to decreases in sales of product partially offset by adjustments for accounting for labor hours for all segments that increased allocation to Cost of Product beginning in 2026 as discussed above. 
 
Cost of product for the  nine months ended  September 30, 2026, was $327,080, as compared to $755,393, for the same period in 2025. for a  decrease of  57%. Gross profit for cobalt products for the  nine months ended  September 30, 2026 was $271,009 compared to  $761,754 for the same period in 2025. This is a  decrease of $490,745, or approximately  64%. Gross profit percentages were  45% and  50% respectively. The  decrease in cost of product was due to decreased sales in the  nine months ended  September 30, 2026.
 
Operating costs and expenses in this segment were  $205,557 for the three months ended  September 30, 2026, compared to  $237,051 for the same period in 2025. This  decrease in operating costs and expenses of  $31,494 was due to decreased Salary expense. We had a net loss for Cobalt Products of  $160,566 for the three months ended  September 30, 2026, as compared to net income of  $245,837 for the same period in 2025. The decrease in net income of $406,403, or approximately 165%, was attributable to decreased sales.
 
Operating costs and expenses in this segment were  $615,105 for the  nine months ended  September 30, 2026, compared to  $761,183 for the same period in 2025. This  decrease in operating costs and expenses is also due to waste expense of $129,000 in the  nine months ended  September 30, 2025 compared to no such expense in 2026. We had a net loss for Cobalt Products of  $344,096 for the  nine months ended  September 30, 2026, as compared to net income of  $571 for the same period in 2025. The  decrease in net income of $344,667 was attributable to decreased sales.
 

Calibration & Reference Products (formerly Nuclear Medicine Standards)

Sales of product in the Calibration & Reference Products segment for the three months ended September 30, 2026, were $737,222, compared to $961,093 for the same period in 2025. This represents a decrease in sales of $223,871, or approximately 23%. 

 

Sales of product in the Calibration & Reference Products segment for the nine months ended September 30, 2026, were $2,675,043, compared to $3,301,673 for the same period in 2025. This represents a decrease in sales of $626,630, or approximately 19%. We had a decrease in sales in the three months and nine months ended September 30, 2026 partially because of catch-up revenue that occurred in 2025 due to pent up demand from a global shortage of Cobalt-57 radioisotope that happened during 2024 which resulted in increased sales during the nine months end September 30, 2025. Additionally, we have a growing backlog of orders which we weren't able to deliver in the nine months ended September 30, 2026 due to another global interruption of Cobalt-57 supply.

 

Due to an ongoing global shortage of Gadolinium-153 radioisotope beginning in January 2024, we have been unable to manufacture and sell any products that utilize this radioisotope since January 2025. We began manufacturing these products again in October 2026 and expect a period of catch up.

 

In July of 2026 there was a global interruption of Cobalt-57 raw material supply which has materially impacted our sales of various Calibration & Reference Products. We estimate the impact to be approximately $250,000 in Q3 of 2026. We currently have a backlog of approximately $300,000. The outage may also impact Fourth Quarter sales of Cobalt-57 products if global suppliers are unable to catch-up on deliveries so that we can clear our backlog. We continue to search for additional suppliers of key radioisotope raw materials.

 

Cost of product for our Calibration & Reference Products segment for the three months ended September 30, 2026, was $415,274, as compared to $512,156 for the same period in 2025. The decrease in cost of product in the period-to-period comparison of $96,882, or 19%, was due to decreased sales partially offset by adjustments for accounting for labor hours to increase allocation to Cost of Product among all segments beginning in 2026 as discussed in more detail above. Gross profit for our Calibration & Reference Products segment for the three months ended September 30, 2026 was $321,948 compared to $448,937 for the same period in 2025. This is a decrease in gross profit of $126,989, or approximately 28% due to the decreased sales.

 

Cost of product for our Calibration & Reference Products segment for the nine months ended September 30, 2026, was $1,583,142, as compared to $1,656,980 for the same period in 2025. The decrease in cost of product in the period-to-period comparison of $73,838, or 4%, was due to decreased sales partially offset by adjustments for accounting for labor hours to increase allocation to Cost of Product among all segments beginning in 2026 as discussed in more detail above. Gross profit for our Calibration & Reference Products segment for the nine months ended September 30, 2026 was $1,091,901 compared to $1,644,693 for the same period in 2025. This is a decrease in gross profit of $552,792, or approximately 34% was due to decreased sales.

 

Operating costs and expenses for this segment for the three months ended September 30, 2026 increased to $566,912, from $548,055 for the same period in 2025. This is an increase of $18,857, or approximately 3%. Operating costs and expenses for this segment for the nine months ended September 30, 2026 increased to $1,553,315, from $1,514,635 for the same period in 2025. This is an increase of $38,680, or approximately 3%, The increases to operating costs and expenses during the three months and nine months ended September 30, 2026, as compared to the same periods in 2025, were the result of increased professional fees.

 

Net loss for this segment for the three months ended September 30, 2026 was $244,964, compared to net loss of $99,118 for the same period in 2025. This is an increase of net loss of $145,846 and was largely the result of decreased sales. 

 

Net loss for this segment for the nine months ended September 30, 2026 was $461,414, compared to net income of $130,058 for the same period in 2025. This is a decrease of net income of $591,472 and was largely the result of decreased sales. 

 

26

 

Medical Device Products.

For the three months ended September 30, 2026 we had sale of product in the Medical Device Products segment of $36,514 compared to $65,757 for the same period ending September 30, 2025. This represents a decrease in sales of $29,243, or approximately 44%. 

 

For the nine months ended September 30, 2026 we had sale of product in the Medical Device Products segment of $166,584 compared to $176,476 for the same period ending September 30, 2025. This represents an decrease in sales of $9,892, or approximately 6%.

 

Cost of product for our Medical Device Products segment for the three months ended September 30, 2026, was $40,463, as compared to $59,433 for the same period in 2025. The decrease in cost of product in the period-to-period comparison of $18,970, or 32%, was due to decreased sales. Gross profit for our Medical Device Products segment for the three months ended September 30, 2026 was($3,949) compared to $6,324 for the same period in 2025. This is a decrease in gross profit of $10,273, or approximately 162%.

 

Cost of product for our Medical Device Products segment for the nine months ended September 30, 2026, was $122,944, as compared to $153,634 for the same period in 2025. The decrease in cost of product in the period-to-period comparison of $30,690, or 20%, was due decreased sales and sales of higher margin products during the nine-month period ended September 30, 2026 compared to the same period in 2025. Gross profit for our Medical Device Products segment for the nine months ended September 30, 2026 was $43,640 compared to $22,842 for the same period in 2025. This is an increase in gross profit of $20,798, or approximately 91% due to sales of higher margin products.

 

Operating costs and expenses for this segment for the three months ended September 30, 2026 were $297,152 compared to $193,939 in the same period in 2025 which is an increase in operating expenses of $103,213. Operating costs and expenses for this segment for the nine months ended September 30, 2026 were $722,416 compared to $593,431 in the same period in 2025 which is an increase in operating expenses of $128,985 The increased operating expenses during the three months and nine months ended September 30, 2026, as compared to the same periods in 2025, were due to increased research and development related to the startup of this new business segment. 

 

Net loss for this segment for the three months ended September 30, 2026 was $301,101, compared to net loss of $187,615 for the same period in 2025. This is an increase in net loss of $113,486. Net loss for this segment for the nine months ended September 30, 2026 was $678,776, compared to net loss of $570,589 for the same period in 2025. The increases to net loss of $108,187 during the three-month and nine-month periods were due to increased operating costs.

 

Fluorine Products.

For the three months and nine months ended September 30, 2026 and the three months and nine months ended September 30, 2025, we had no sales and cost of product in our Fluorine Products segment.

 

During the three months ended September 30, 2026, we incurred $64,457 of expenses related to maintenance of plans, designs, and other assets for a proposed de-conversion facility, as compared to $26,095 for the same period in 2025. During the nine months ended September 30, 2026, we incurred $128,125 of expenses related to maintenance of plans, designs, and other assets for a proposed de-conversion facility, as compared to $82,330 for the same period in 2025. The increases in expenses for the three-month and nine-month periods were due to legal expense related to the DUF6 Sale.

 

During the three months ended September 30, 2026 and 2025 we received $0 and $20,000 respectively in extension payments related to the DUF6 Asset Sale. During the nine months ended September 30, 2026 and 2025 we received $20,000 and $60,000 in extension payments respectively. The DUF6 Asset Sale was terminated in February as described in more detail above. These $10,000 extension payments received monthly from April 2025 until March 2026 were included in Other Income on our Statement of Operations.

 

27

 

LIQUIDITY AND CAPITAL RESOURCES

 

At September 30, 2026, we had cash and cash equivalents of $711,288 as compared to $1,695,158 at December 31, 2025. This is a decrease of $983,870 or approximately 58% was largely due to increased net loss and purchases of property, plant, and equipment. For the nine months ended September 30, 2026, net cash used in operating activities was $1,132,543 and for the nine months ended September 30, 2025, net cash provided by operating activities was $210,043. The decrease in cash provided by operating activities was a result of an increase in net loss in the nine months ended September 30, 2026.

 

Inventories at September 30, 2026 totaled $653,440, and inventories at December 31, 2025 totaled $875,449. Our inventory consists of work in process material for our Theranostics Products, Cobalt Products, Calibration & Reference Products, and Medical Device Products segments.

 

Cash used in investing activities was $205,570 for the nine months ended September 30, 2026, and cash used in investing activities was $254,391 for the same period in 2025. The cash used in both periods was for the purchase of equipment. 

 

Cash provided by financing activities was $394,749 during the nine months ended September 30, 2026, and cash used in financing activities for the same period in 2025 was $203,652. During the nine months ended September 30, 2026, cash paid for interest was $47,431 as compared to cash paid for interest of $160,973 for the same nine-month period in 2025. Additionally, during the nine months ended September 30, 2026, we received $26,566 in proceeds from the sale of our common stock through our Employee Stock Purchase Plan, as compared to $14,883 in proceeds from the sale of our common stock through our Employee Stock Purchase Plan in the nine months ended September 30, 2025. During the nine months ended September 30, 2026, principal payments on notes payable were $131,817, as compared to $264,050 for the same period in 2025.

 

On June 23, 2026, we borrowed $500,000 from Kershner Grosso & Co., which is owned by the Company's Chairman of the Board. (the 2026 Promissory Note). Further details can be found under Note 6 "Debt" in the notes to the financial statements in this report.

 

In February 2026, we declared our annual dividend on the Series C Preferred Stock. Dividends payable totaled $243,780 at that time. Some holders of the Series C Preferred Stock elected to settle their dividend payments with shares of the Company’s common stock in lieu of cash. The Company issued 573,570 shares of common stock in lieu of a dividend payment of $48,180. $39,300 of dividend payable was settled with cash. $156,300 in dividends will be settled by the end of 2026.

 

Total decrease in cash, cash equivalents, and restricted cash for the nine months ended September 30, 2026, was $943,364 compared to a cash, cash equivalents, and restricted cash decrease of $248,000 for the same period in 2025.

 

We expect that cash from operations, cash raised via equity financing, and our current cash balance will be sufficient to fund operations for the next twelve months. Our future liquidity and capital funding requirements will depend on numerous factors, including commercial relationships, technological developments, market factors, and available financing. There is no assurance that additional capital and financing will be available on acceptable terms to the Company or at all.

 

28

 

Debt

 

In December 2013, we entered into a promissory note agreement with its then Chairman of the Board and one of our major shareholders, pursuant to which we borrowed $500,000 (the 2013 Promissory Note) which has a current maturity date of March 31, 2031. The 2013 Promissory Note is unsecured and bears interest at 6% per annum and was originally due June 30, 2014. According to the terms of the 2013 Promissory Note, at any time, the lenders could settle any or all of the principal and accrued interest with shares of our common stock. Between 2014 and 2024, the 2013 Promissory Note was modified to extend the maturity date five times with the fifth modification extending the maturity date to March 31, 2026. In August 2025, the 2013 Promissory Note was modified again to extend the maturity date to March 31, 2028, with all remaining terms unchanged. On June 30, 2026, the 2013 Promissory Note was modified again to extend the maturity date to March 31, 2031, add a voluntary lender conversion right at $0.07 per share of the Company's common stock, and add a Company forced-conversion right exercisable if our stock trades for thirty (30) consecutive Trading Day at or above a VWAP of $0.12 per share.

 

In April 2018, we borrowed $120,000 from its then Chief Executive Officer and Chairman of the Board pursuant to a promissory note (the 2018 Promissory Note) which has a current maturity date of March 31, 2031. The 2018 Promissory Note accrues interest at 6% per annum, which is payable upon maturity of the 2018 Promissory Note. The 2018 Promissory Note was originally unsecured and originally matured on August 1, 2018. At any time, lenders could settle any or all of the principal and accrued interest with shares of our common stock. Between 2018 and 2024, the 2018 Promissory Note was modified to extend the maturity date six times with the sixth modification extending the maturity date to March 31, 2026. In August 2025, the 2018 Promissory Note was modified to extend the maturity date to March 31, 2028, with all remaining terms unchanged. On June 30, 2026, the 2018 Promissory Note was modified to extend the maturity date to March 31, 2031, add a voluntary lender conversion right at $0.07 per share of the Company's common stock, and add a Company forced-conversion right exercisable if our stock trades for thirty (30) consecutive Trading Day at or above a VWAP of $0.12 per share.

 

In December 2019 and February 2020, we borrowed an aggregate of $1,000,000 from four of the Company’s major shareholders pursuant to a promissory note (the 2019 Promissory Note) which has a current maturity date of March 31, 2031. The 2019 Promissory Note bears an interest rate of 4% annually and was originally due December 31, 2022. According to the terms of the 2019 Promissory Note, at any time, the lenders could settle any or all of the principal and accrued interest with shares of the Company’s common stock based on the average closing price of the Company’s common stock for the 20 days preceding the payment. In December 2022, the 2019 Promissory Note was modified to extend the maturity date to December 31, 2024, with all remaining terms unchanged. In February 2024, the 2019 Promissory Note was modified to extend the maturity date to March 31, 2026, with all remaining terms unchanged. In August 2025, the 2019 Promissory Note was modified to extend the maturity date to March 31, 2028, with all remaining terms unchanged. On June 30, 2026, the 2019 Promissory Note was modified to extend the maturity date to March 31, 2031, add a voluntary lender conversion right at $0.07 per share of the Company's common stock, and add a Company forced-conversion right exercisable if our stock trades for thirty (30) consecutive Trading Day at or above a VWAP of $0.12 per share.

 

In June 2026, we borrowed $500,000 from Kershner Grosso & Co., which is owned by the Company's Chairman of the Board. (the 2026 Promissory Note). The 2026 Promissory Note has a maturity date of June 30, 2031 with an interest rate of 5% per annum, and such interest shall be calculated and paid annually on each anniversary date of the Signing Date. For the first two years of the Note, the Company may elect to pay interest either in cash or in kind. However, following the two-year period, interest on the outstanding principal shall be payable only in cash to the Lender. The Lender has the right to convert the Note at any time to shares of Common Stock at a conversion price of $0.07, rounded down to the nearest share. Beginning six months after the Signing Date, the Company may call the outstanding Note, plus accrued interest, for conversion into Common Stock, so long as the volume weighted-average closing price of the Company stock over a 30 day period is greater than $0.12 per share. 

 

CRITICAL ACCOUNTING POLICIES

 

From time-to-time, management reviews and evaluates certain accounting policies that are considered to be significant in determining our results of operations and financial position.

 

A description of the Company’s critical accounting policies that affect the preparation of the Company’s financial statements is set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 31, 2026.

 

29

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act), that are designed to ensure that material information relating to us is made known to the officers who certify our financial reports and to other members of senior management and the Board of Directors. These disclosure controls and procedures are designed to ensure that information required to be disclosed in our reports that are filed or submitted under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

 

Management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness, as of September 30, 2026, of our disclosure controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2026.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II – OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We are not a party to any legal proceedings. Management is not aware of any legal proceedings proposed to be instituted against us. However, from time to time, we may be subject to claims and litigation generally associated with any business operating in the ordinary course.

 

30

 

ITEM 1A. RISK FACTORS

 

There have been no material changes or updates to the risk factors previously disclosed in Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2025, except as set forth below:

 

If the FDA concludes that we have failed to comply with applicable regulations, it could take various actions including: issuing warning letters, imposing civil or criminal penalties, suspending regulatory approvals, requiring product recalls, seizing products, or enjoining future violations. Such enforcement actions could have a material adverse effect on our business, results of operations and financial condition.

 

We are subject to ongoing FDA regulations, including complying with the FDA’s current Good Manufacturing Practice (cGMP) requirements, and are subject to regular inspections of our facilities.

 

In April 2025, an FDA inspection at our Idaho Falls facility resulted in an Official Action Indicated ("OAI"). RNX developed and implemented corrective actions and submitted our 15-day, 90-day, and 180-day, 270-day, and subsequently submitted our 1-year updates. In response to the FDA Form 483 issued in April 2025, the Company completed all planned corrective and preventive actions. A request for inspection closeout was submitted to the FDA on June 19, 2026. In addition, the Company continues to execute initiatives designed to strengthen its Quality Management System, with all actions scheduled for completion in July 2026 completed on time. There is a risk of additional action by the FDA up to and including a manufacturing and distribution hold or a warning letter. While we believe that our corrective actions in response to the OAI will be deemed satisfactory, there can be no assurance that the FDA will not require additional corrective actions or take further actions as listed above.

 

In the three months ended March 31, 2026, we had two product recalls. Both recalls are being conducted with the knowledge of the FDA. The first was a voluntary recall of our Generic Sodium Iodide I-131 due to the discovery of septum in our finished product vials on January 26, 2026. We had recently been approved by the FDA to implement new septum for our finished products, with this change we discovered the septum did not perform equivalent to our previous testing and validation. The impact from this recall was limited to that first batch. The second recall was on February 19, 2026. We discovered during an internal review that specific lots of our Dibasic Sodium Phosphate Capsules that may be provided with our Generic Sodium Iodide I-131 kits manufactured between 2022 and 2025 were out of specification for final capsule weight. We initiated a voluntary recall of specific lots of our Dibasic Sodium Phosphate Capsules shipped between August 19, 2024 to February 17, 2026. We notified affected pharmacies, clinics, and veterinarians of the voluntary recall. We continue to provide Generic Sodium Iodide I-131, which was not impacted, to the majority of our customers. Both voluntary recalls have been fully executed and are currently awaiting formal closeout by the FDA.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 5. OTHER INFORMATION

 

During the quarter ended September 30, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

31

  
 

ITEM 6. EXHIBITS

 

Exhibit No.

Description

 

2.1

Asset Purchase Agreement dated June 25,2026 by and between Radnostix,Inc. and Lucerno Dynamics. LLC (incorporated by reference to Exhibit 2.1 to the Company’s Current report on Form 8-k filed on July 1, 2026) 

 

3.1

Certificate of Amendment to Statement of Designation of the Series C Convertible Redeemable Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current report on Form 8-K filed on May 14, 2026) 

 

31.1*

Certification by the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

 

31.2*

Certification by the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

 

32.1**

Certification by the Chief Executive Officer furnished pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

32.2**

Certification by the Chief Financial Officer furnished pursuant to 18 U.S.C. Section 1350 adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

101.INS*

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

101.SCH*

Inline XBRL Taxonomy Extension Schema Document

 

101.CAL*

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

101.DEF*

Inline XBRL Taxonomy Extension Definition Linkbase Document

 

101.LAB*

Inline XBRL Taxonomy Extension Label Linkbase Document

 

101.PRE*

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

104

Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101).

 


* Filed herewith.

** Furnished herewith.

 

32

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: November 16, 2026

Radnostix Inc.

   
     
 

By:

/s/ Shahe Bagerdjian

   

Shahe Bagerdjian

   

Chief Executive Officer

     
     
 

By:

/s/ W. Matthew Cox

   

W. Matthew Cox

   

Chief Financial Officer

 

33

Keep reading